WELCOME TO THE DIVISION OF CLINICAL PHARMACOLOGY AT UCT

The Division is located in the Old Main Building of the Groote Schuur Hospital complex.

We strive to promote drug discovery and the rational and cost-effective use of medicines to serve the health needs of people in Africa through teaching, mentorship, research, and clinical consultation. We are a World Health Organization Collaborating Centre for Medicines Information.

TEACHING

The division teaches undergraduate medical and physiotherapy students. The focus of our teaching to medical students is rational prescribing of essential medicines for primary care. Most of the teaching is done in smaller groups. Pharmacology teaching is integrated in the 2nd through to 6th MBChB years, with specific pharmacology blocks in the 4th and 5th years – we also teach physiotherapy undergraduate students.

The Division offers post-graduate training at several scientific levels and one clinical specialist level. Information is available from the Faculty of Health Science postgraduate-programme handbook 

BMedSc (Hons)

The pharmacology honours programme is a one year full-time course aimed at graduates with backgrounds in life science, chemistry or pharmacy who wish to pursue careers in technical areas or are considering higher degrees and careers in research.. The course introduces students to techniques (cell culture, mass spectrometry, chromatography, and antimicrobial assays). Each student undertakes a research project, usually in natural products, toxicology, or clinical bioanalysis. A series of theory modules are taught in parallel with the research project. Prospective applicants can contact the course coordinator Ms Sharne Dunn (sharne.dunn@uct.ac.za).

MPhil

This degree offers postgraduate training in the drug development process, via coursework and a research projectwith a mini-dissertation. The objective of this course is to educate and train researchers in the clinical pharmacology of drug development. The curriculum is comprised of the following modules: drug development, bioanalysis, pharmacometrics, pharmacokinetic-pharmacodynamic principles The course is undertaken full-time over two years or part-time over a longer period. Prospective applicants can contact the course convenor Prof Lubbe Wiesner.

MSc (Med)

This dissertation-based degree is aimed at graduates with an Honours degree in life sciences or chemistry, or with a pharmacy or medical degree who wish to pursue a career in research. Students will develop and execute research on a project focused in one of the Division’s major research areas (pharmacometrics; preclinical drug development; clinical pharmacokinetics; pharmacovigilance; pharmacogenetics; pharmacotherapy of HIV, malaria, and tuberculosis). The degree programme requires registration for a minimum of two years. Depending on progress and the nature of the project, students may be eligible to upgrade to a PhD in the 3rd year of study. Enrolment in the MSc programme is dependent on availability of funding and supervision capacity. Prospective candidates should contact the research groups directly to enquire (Clinical and preclinical pharmacokinetics and drug discovery – Prof Lubbe Wiesner; antimalarial research – Prof Karen Barnes; pharmacovigilance – A/Prof Karen Cohen or antiretroviral pharmacotherapy - Prof Gary Maartens; tuberculosis pharmacotherapy – Prof Helen McIlleron; pharmacogenomics – A/Prof Phumla Sinxadi).

PhD (Med)

This dissertation-based degree is aimed at graduates with a Master’s degree in life sciences, pharmacy or chemistry, or a degree in medicine. Students will develop and execute original research on a project focused in one of the Division’s major research areas. The project will be supervised by one or more senior academics. Prospective Doctoral candidates should contact the research groups directly to enquire about availability of funding and supervision capacity (see under MSc (Med) above). For PhD in pharmacometrics please contact pharmacometrics research group at pharmacometrics@uct.ac.za or visit www.pharmacometrics.uct.ac.za

MMed (Clin Pharm)

This specialist qualification is only offered to medical graduates (MBChB) wishing to specialise in Clinical Pharmacology. The registrar rotation is a 4 year programme. All candidates need to write the exams set by the Colleges of Medicine of South Africa and submit a mini-dissertation. Prospective candidates should contact Professor Marc Blockman.

Information on course outlines is available in the Faculty of Health Science postgraduate-programme handbook. Please click here for the College of Clinical Pharmacology Cirriculum. For applications, please email Ruwayda Philander.

CLINICAL SERVICES

The division provides a clinical and laboratory pharmacology service to Groote Schuur hospital as well as secondary and primary centres within our drainage area. Therapeutic drug monitoring with input from clinical pharmacologists is offered for a wide variety of drugs, including antiretroviral and anti-tuberculosis drugs. Clinical consultation is offered to regional hospitals.  A copy of the test request form is available here: Pharmacology Test Request Form. The division plays an important role in providing policy advice in the rational and cost effective use of drugs for local hospitals, the Western Cape Government Health Provincial Coding  and Antimicrobial Stewardship Committees, the National Essential Medicines List Committee, and international guidelines on HIV, TB, and malaria. The division also contributes to national medicines regulatory and pharmacovigilance activities of the South African Health Products Regulatory Authority (SAHPRA) ; and internationally through the Uppsala drug safety monitoring centre. The Medicines Information Centre provides a telephonic consultation service for healthcare professionals and runs the National HIV & TB Healthcare Worker Helpline. The division produces the South African Medicines Formulary, currently in its 14th edition. 

SAMF

WELCOME TO THE SOUTH AFRICAN MEDICINES FORMULARY. You will now be able to access all of SAMF's content online. The University of Cape Town, Division of Clinical Pharmacology and the South African Medical Association are proud to deliver the SAMF content to your phone, your tablet and your desktop.

samf-app.com

RESEARCH

We conduct clinical research focused on drugs for malaria, tuberculosis, and HIV. The research in these fields is broad and encompasses drug discovery, pharmacokinetics and pharmacodynamics, pharmacometrics, pharmacogenomics, clinical trials, pharmacovigilance, and pharmacoeconomic evaluation. Our peer-reviewed publications for the last 3 years are listed below.

Pharmacokinetic Laboratory

The laboratory plays a key research role in evaluating PK of drug/metabolite concentrations in patient samples. The laboratory has been awarded funding as an International Pharmacology Specialty Laboratory from two NIH networks: the AIDS Clinical Trials Group and the International Maternal Pediatric Adolescent AIDS Clinical Trials Group.

Liquid chromatography tandem mass spectrometry is used as bioanalysis platform and various extraction techniques are used for sample preparation depending on matrix complexity and the calibration range. Assays are validated according to FDA and EMA guidelines and analysis is done according to DAIDS GCLP guidelines.  The laboratory is well equipped with 9 liquid chromatography tandem mass spectrometry workstations, including 2 highly sensitive systems for detecting very low concentrations (e.g., CSF, intracellular, and unbound drugs), and a high-resolution Q-TOF system used for clinical toxicology, natural product research, and proteomics.

For more information about the Pharmacokinetic Laboratory please refer to 

https://health.uct.ac.za/pk-laboratory

Laboratory Director: Prof Lubbe Wiesner

Pharmacometrics Group

Pharmacometrics, or quantitative pharmacology, is the science quantifying drug and disease information with the purpose to aid efficient drug development or regulatory decisions, or to improve the clinical use of drugs.

Mathematical and statistical models, also known as nonlinear mixed-effects models, are used to describe the relationship between drug dose, exposure (pharmacokinetics), and response (pharmacodynamics) for both desired and undesired effects, and individual patient characteristics.

A/Prof Paolo Denti and the pharmacometrics group at the University of Cape Town focus on the investigation of pharmacology of antiretroviral, antituberculosis, and antimalarial agents with the aim of improving the way we treat patients for these infectious diseases. Key research areas are drug-drug interactions that may arise in patients who need concomitant treatment for these diseases; the optimisation of dosing in neglected populations (such as children and pregnant women); pharmacogenomics and the characterisation of PK/PD relationships.

The group is part of several international collaborations, including the modelling groups at Uppsala University and the University of Liverpool, and is involved in the analysis of data from clinical trials, sponsored by the European & Developing Countries Clinical Trials Partnership (EDCTP), the US National Institute of Health, the World Health Organisation, the Drugs for Neglected Diseases initiative, the Medical Research Council (South Africa and the United Kingdom), Medicines for Malaria Venture, the Aids Clinical Trials Group and the International Maternal Pediatric Adolescent AIDS Clinical Trials Network.

For more information about the Pharmacometrics group and their research, please refer to http://www.pharmacometrics.uct.ac.za/

Pharmacometrics Group

Antimalarial drugs

Prof Karen Barnes is the founding director of the MRC Collaborating Centre for Optimising Antimalarial Therapy. She leads the Worldwide Antimalarial Resistance Network’s pharmacology group. Her interests are in translational research from drug development, through dose optimisation in vulnerable populations to the comprehensive evaluation of changes in antimalarial treatment policy.

Prof Lubbe Wiesner heads malaria pre-clinical drug development research, in collaboration with Prof Kelly Chibale, using tissue culture and small animal models.

Antiretroviral therapy

Prof Gary Maartens leads research on the effectiveness, adherence, and pharmacoeconomics of antiretroviral therapy in resource-limited settings. Prof Helen McIlleron leads clinical pharmacokinetic research into antiretroviral drug interactions, and dose optimisation in children and pregnancy. A/Prof Karen Cohen leads the antiretroviral pharmacovigilance group. A/Prof Phumla Sinxadi leads pharmacogenomics studies.

Anti-tuberculosis drugs

Prof Helen McIlleron directs anti-tuberculosis clinical pharmacokinetic studies optimising dosing in children and pregnant women, exploring PK/PD relationships, and pharmacogenomics. Prof Gary Maartens leads research on treatment optimisation of HIV-associated tuberculosis and treatment of drug-resistant tuberculosis.

Publications

publication chart

    • 2022

      1. Abdelgawad N, Tshavhungwe MP, Rohlwink U, et al. Population Pharmacokinetic Analysis of Rifampicin in Plasma, Cerebrospinal Fluid, and Brain Extracellular Fluid in South African Children with Tuberculous Meningitis. Antimicrob Agents Chemother 2023; 67: e0147422.
      2.  Amuge P, Lugemwa A, Wynne B, et al. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. lancet HIV 2022; 9: e638–48.
      3.  Asiimwe IG, Blockman M, Cohen K, et al. A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients. Front Pharmacol 2022; 13. DOI:10.3389/fphar.2022.967082.
      4. Asiimwe IG, Blockman M, Cohen K, et al. Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm. CPT Pharmacometrics Syst Pharmacol 2022; 11: 20–9.
      5. Ayton S, Schwitters A, Mantell JE, et al. Male partner age, viral load, and HIV infection in adolescent girls and young women: evidence from eight sub-Saharan African countries. AIDS 2023; 37: 113–23.
      6. Banda CG, Nkosi D, Allen E, et al. Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV. Antimicrob Agents Chemother 2022; 66. DOI:10.1128/aac.00584-22.
      7. Beesham I, Mansoor LE, Joseph Davey DL, et al. Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial. J Acquir Immune Defic Syndr 2022; 91: 26–30.
      8. Bekker A, Capparelli E V, Violari A, et al. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. lancet HIV 2022; 9: e24–31.
      9. Béranger A, Bekker A, Solans BP, et al. Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. Clin Infect Dis 2022; 75: 1037–45.
      10. Chabala C, Turkova A, Hesseling AC, et al. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations. Clin Infect Dis 2022; 74: 1767–75.
      11. Chen L, van Rhee KP, Wasmann RE, et al. Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. J Antimicrob Chemother 2022; 77: 2217–26.
      12. Chisholm BS, Swart AM, Blockman M. South African healthcare workers’ knowledge of dolutegravir’s drug–drug interactions in the first year of its rollout: a cross‐sectional online survey. J Int AIDS Soc 2022; 25. DOI:10.1002/jia2.25885.
      13. Chisholm BS, Swart AM, Blockman M. Training, guideline access and knowledge of antiretroviral interactions: Is the South African private sector being left behind? 2022; 112: 806–11.
      14. Chughlay MF, Barnes KI, El Gaaloul M, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults. Antimicrob Agents Chemother 2022; 66: e0158421.
      15. Chughlay MF, Chalon S, El Gaaloul M, et al. Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs. Am J Trop Med Hyg 2022; 107: 804–14.
      16. Cindi Z, Kawuma AN, Maartens G, et al. Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. J Infect Dis 2022; 226: 1616–25.
      17. Court R, Gausi K, Mkhize B, et al. Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin-resistant tuberculosis. Br J Clin Pharmacol 2022; 88: 3548–58.
      18. De Nicolò A, Calcagno A, Motta I, et al. The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. Antimicrob Agents Chemother 2022; 66: e0013622.
      19. Denti P, Wasmann RE, Francis J, et al. One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation. Lancet Child Adolesc Heal 2022; 6: 9–10.
      20. Denti P, Wasmann RE, van Rie A, et al. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. Clin Infect Dis 2022; 75: 141–51.
      21. Flegg JA, Humphreys GS, Montanez B, et al. Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990–2020. PLOS Comput Biol 2022; 18: e1010317.
      22. Gausi K, Chirehwa M, Ignatius EH, et al. Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2022; 77: 2489–99.
      23. Gebreyesus MS, Decloedt EH, Cluver CA, et al. Population pharmacokinetics of esomeprazole in patients with preterm preeclampsia. Br J Clin Pharmacol 2022; 88: 4639–45.
      24. Griesel R, Sinxadi P, Kawuma A, et al. Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population. J Antimicrob Chemother 2022; 77: 3110–7.
      25. Haas DW, Abdelwahab MT, van Beek SW, et al. Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. J Infect Dis 2022; published online Jan 29. DOI:10.1093/infdis/jiac024.
      26. Haas DW, Mngqibisa R, Francis J, et al. Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenet Genomics 2022; 32: 24–30.
      27. Hughes JA, Solans BP, Draper HR, et al. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis. Clin Infect Dis 2022; 75: 1772–80.
      28. Jacobs TG, Schouwenburg S, Penazzato M, et al. What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies. lancet HIV 2022; 9: e649–57.
      29. Joseph Davey D, Nyemba DC, Castillo-Mancilla J, et al. Adherence challenges with daily oral pre-exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study. J Int AIDS Soc 2022; 25: e26044.
      30. Joubert A, Kellermann T, Joubert A, et al. Simultaneous Determination of Carvedilol, Enalaprilat, and Perindoprilat in Human Plasma Using LC–MS/MS and Its Application to a Pharmacokinetic Pilot Study. Chromatographia 2022; 85: 455–68.
      31. Joubert AA, Joubert AA, van der Merwe M, et al. Validation of a quantitative multiplex LC-MS/MS assay of carvedilol, enalaprilat, and perindoprilat in dried blood spots from heart failure patients and its cross validation with a plasma assay. J mass Spectrom Adv Clin lab 2023; 27: 7–17.
      32. Kagoro FM, Allen E, Mabuza A, et al. Making data map-worthy—enhancing routine malaria data to support surveillance and mapping of Plasmodium falciparum anti-malarial resistance in a pre-elimination sub-Saharan African setting: a molecular and spatiotemporal epidemiology study. Malar J 2022; 21: 207.
      33. Kagoro FM, Barnes KI, Marsh K, et al. Mapping genetic markers of artemisinin resistance in Plasmodium falciparum malaria in Asia: a systematic review and spatiotemporal analysis. The Lancet Microbe 2022; 3: e184–92.
      34. Kawuma AN, Wasmann RE, Dooley KE, Boffito M, Maartens G, Denti P. Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. Antimicrob Agents Chemother 2022; 66: e0021522.
      35. Kufa T, Radebe F, Cutler E, et al. Recency of HIV infection, antiretroviral therapy use and viral loads among symptomatic sexually transmitted infection service attendees in South Africa. S Afr Med J 2022; 112: 13502.
      36. Loveday M, Goga A, Dhai A, et al. Ethically acceptable consent approaches to adolescent research in South Africa. South Afr J HIV Med 2022; 23: 1385.
      37. Mansoor R, Commons RJ, Douglas NM, et al. Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Med 2022; 20: 85.
      38. Mathad JS, Savic R, Britto P, et al. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Clin Infect Dis 2022; 74: 1604–13.
      39. McIlleron H. Treating children with tuberculosis-Using pharmacometrics to do better. Br J Clin Pharmacol 2022; 88: 894–6.
      40. Mkhize B, Kellermann T, Norman J, et al. Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk. J Pharm Biomed Anal 2022; 215: 114774.
      41. Mondleki E, Banda CG, Chandiwana NC, et al. Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV. South Afr J HIV Med 2022; 23: 1452.
      42. Montanha MC, Fabrega F, Howarth A, et al. Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. Clin Pharmacokinet 2022; 61: 375–86.
      43. Odayar J, Orrell C, Phillips TK, et al. Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study. Clin Infect Dis 2022; 75: 761–7.
      44. Perumal R, Arodola-Oladoyinbo O, Naidoo A, et al. Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen. Int J Tuberc Lung Dis 2022; 26: 766–74.
      45. Perumal R, Naidoo K, Naidoo A, et al. The impact of enteral feeding and therapeutic                 monitoring of rifampicin with dose escalation in critically ill patients with tuberculosis. Int J Infect Dis 2023; 126: 174–80.
      46. Post FA, Sinxadi P. Tenofovir disoproxil and renal mitochondrial toxicity: more studies in Africans are needed. AIDS 2022; 36: 1047–8.
      47. Radtke KK, Hesseling AC, Winckler JL, et al. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Clin Infect Dis 2022; 74: 1372–81.
      48. Rosenthal PJ, Björkman A, Dhorda M, et al. Cooperation in Countering Artemisinin Resistance in Africa: Learning from COVID-19. Am J Trop Med Hyg 2022; 106: 1568–70.
      49. Salerno SN, Capparelli E V, McIlleron H, et al. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. Pharmacotherapy 2022; published online May 24. DOI:10.1002/phar.2703.
      50. Schwitters A, McCracken S, Frederix K, et al. High HIV prevalence and associated factors in Lesotho: Results from a population-based survey. PLoS One 2022; 17: e0271431.
      51. Stepniewska K, Allen EN, Humphreys GS, et al. Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data. BMC Med 2022; 20: 350.
      52. Stepniewska K, Humphreys GS, Gonçalves BP, et al. Efficacy of Single-Dose Primaquine With Artemisinin Combination Therapy on Plasmodium falciparum Gametocytes and Transmission: An Individual Patient Meta-Analysis. J Infect Dis 2022; 225: 1215–26.
      53. Tanneau L, Karlsson MO, Diacon AH, et al. Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. Clin Pharmacokinet 2022; 61: 1177–85.
      54. Taylor J, Mpofu R, Blockman M. The GLP-1 receptor agonists: what’s all the (cardiovascular) hype about? South African Gen Pract 2022; 3: 118–20.
      55. Thorpe R, Blockman M, Talberg H, Burgess T. The knowledge and attitudes of South African-based runners regarding the use of analgesics during training and competition. South African J Sport Med 2022; 34. DOI:10.17159/2078-516X/2022/v34i1a13976.
      56. Tikiso T, McIlleron H, Abdelwahab MT, et al. Population pharmacokinetics of ethambutol in African children: a pooled analysis. J Antimicrob Chemother 2022; 77: 1949–59.
      57. Tikiso T, McIlleron H, Burger D, et al. Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. Br J Clin Pharmacol 2022; 88: 403–15.
      58. Turkova A, Waalewijn H, Chan MK, et al. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. lancet HIV 2022; 9: e627–37.
      59. Turkova A, Wills GH, Wobudeya E, et al. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. N Engl J Med 2022; 386: 911–22.
      60. Upton CM, Steele CI, Maartens G, Diacon AH, Wiesner L, Dooley KE. Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). J Antimicrob Chemother 2022; 77: 1720–4.
      61. van Beek SW, Tanneau L, Meintjes G, et al. Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment. Open forum Infect Dis 2022; 9: ofac372.
      62. van der Laan LE, Garcia-Prats AJ, Schaaf HS, et al. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis. Antimicrob Agents Chemother 2022; 66: e0226421.
      63. van Rensburg R, Nightingale S, Brey N, et al. Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS). Clin Infect Dis 2022; 75: 399–405.
      64. van Rhee KP, Smit C, Wasmann RE, et al. Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. Clin Pharmacokinet 2022; 61: 1167–75.
      65. Wasserman S, Brust JCM, Abdelwahab MT, et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother 2022; 77: 1146–54.
      66. Watson DJ, Evans A, Blockman M, Wiesner L. Detection of karakin poisoning using a targeted mass spectrometric workflow. S Afr Med J 2022; 112: 901–3.
      67. Watson DJ, Laing L, Beteck RM, Gibhard L, Haynes RK, Wiesner L. The evaluation of ADME and pharmacokinetic properties of decoquinate derivatives for the treatment of malaria. Front Pharmacol 2022; 13: 957690.
      68. Weld ED, Waitt C, Barnes K, Garcia Bournissen F. Twice neglected? Neglected diseases in neglected populations. Br J Clin Pharmacol 2022; 88: 367–73.
      69. Wilkins JJ, Svensson EM, Ernest JP, Savic RM, Simonsson USH, McIlleron H. Pharmacometrics in tuberculosis: progress and opportunities. Int J Antimicrob Agents 2022; 60: 106620.
      70. Wilkinson M, Gray AL, Wiseman R, et al. Health Technology Assessment in Support of National Health Insurance in South Africa. Int J Technol Assess Health Care 2022; 38: e44.
      71. Zuma P, Joubert A, van der Merwe M, et al. Validation and application of a quantitative LC-MS/MS assay for the analysis of first-line anti-tuberculosis drugs, rifabutin and their metabolites in human breast milk. J Chromatogr B Analyt Technol Biomed Life Sci 2022; 1211: 123489. .

    • 2021

      1. Abdelwahab MT, Court R, Everitt D, Diacon AH, Dawson R, Svensson EM, Maartens G, Denti P. Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. Antimicrob Agents Chemother 2021; 65: e02687-20.
      2. Abdelwahab MT, Wasserman S, Brust JCM, Dheda K, Wiesner L, Gandhi NR, Warren RM, Sirgel FA, Meintjes G, Maartens G, Denti P. Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis. Antimicrob Agents Chemother 2021; 65: e0138121.
      3. Anyorigiya TA, Castel S, Mauff K, Atuguba F, Ogutu B, Oduro A, Dosoo D, Asante K-P, Owusu-Agyei S, Dodoo A, Hodgson A, Binka F, Workman LJ, Allen EN, Denti P, Wiesner L, Barnes KI. Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria. Malar J 2021; 20: 18.
      4. Asiimwe IG, Waitt C, Sekaggya‐Wiltshire C, Hutchinson C, Okello E, Zhang EJ, Semakula JR, Mouton JP, Cohen K, Blockman M, Lamorde M, Jorgensen AL, Pirmohamed M. Developing and Validating a Clinical Warfarin Dose‐Initiation Model for Black‐African Patients in South Africa and Uganda. Clin Pharmacol Ther 2021; 109: 1564–74.
      5. Berg K, Vermeulen M, Louw VJ, Murphy EL, Maartens G. Undisclosed HIV status and antiretroviral therapy use among South African blood donors. Transfusion 2021; 61: 2392–400.
      6. Bossard C, Schramm B, Wanjala S, Jain L, Mucinya G, Opollo V, Wiesner L, Van Cutsem G, Poulet E, Szumilin E, Ellman T, Maman D. High prevalence of NRTI and NNRTI drug resistance among ART-experienced, hospitalized inpatients. JAIDS J Acquir Immune Defic Syndr 2021; Publish Ah: 883–8.
      7. Brust JCM, Gandhi NR, Wasserman S, Maartens G, Omar S V, Ismail NA, Campbell A, Joseph L, Hahn A, Allana S, Hernandez-Romieu AC, Zhang C, Mlisana K, Viljoen CA, Zalta B, Ebrahim I, Franczek M, Master I, Ramangoaela L, te Riele J, Meintjes G. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study. Clin Infect Dis 2021; 73: 2083–92.
      8. Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, Pathak S, Mgodi N, Bekker L-G, Donnell DJ, Wilson E, Yuha K, Anderson PL, Agyei Y, Noble H, Rose SM, Baeten JM, Fogel JM, Adeyeye A, Wiesner L, Rooney J, Delany-Moretlwe S. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLOS Med 2021; 18: e1003670.
      9. Chabala C, Turkova A, Hesseling AC, Zimba KM, van der Zalm M, Kapasa M, Palmer M, Chirehwa M, Wiesner L, Wobudeya E, Kinikar A, Mave V, Hissar S, Choo L, LeBeau K, Mulenga V, Aarnoutse R, Gibb D, McIlleron H. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations. Clin Infect Dis 2021; published online Aug 22. DOI:10.1093/cid/ciab725.
      10. Chirehwa MT, Court R, de Kock M, Wiesner L, de Vries N, Harding J, Gumbo T, Maartens G, Warren R, Denti P, McIlleron H. Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. Antimicrob Agents Chemother 2021; 65: e0027821.
      11. Cindi Z, Maartens G, Bradford Y, Venter WDF, Sokhela S, Chandiwana NC, Haas DW, Sinxadi P. Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr 2021; 87: 1002–9.
      12. Court R, Centner CM, Chirehwa M, Wiesner L, Denti P, de Vries N, Harding J, Gumbo T, Maartens G, McIlleron H. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int J Infect Dis 2021; 105: 688–94.
      13. Davis AG, Wasserman S, Maxebengula M, Stek C, Bremer M, Daroowala R, Aziz S, Goliath R, Stegmann S, Koekemoer S, Jackson A, Lai Sai L, Kadernani Y, Sihoyiya T, Liang CJ, Dodd L, Denti P, Crede T, Naude J, Szymanski P, Vallie Y, Banderker I, Moosa S, Raubenheimer P, Lai RPJ, Joska J, Nightingale S, Dreyer A, Wahl G, Offiah C, Vorster I, Candy S, Robertson F, Meintjes E, Maartens G, Black J, Meintjes G, Wilkinson RJ. Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]. Wellcome Open Res 2021; 6: 136.
      14. Decloedt EH, Sinxadi PZ, Wiesner L, Joska JA, Haas DW, Maartens G. Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid. South Afr J HIV Med 2021; 22: 1206.
      15. Denti P, Wasmann RE, van Rie A, Winckler J, Bekker A, Rabie H, Hesseling AC, van der Laan LE, Gonzalez-Martinez C, Zar HJ, Davies G, Wiesner L, Svensson EM, McIlleron HM. Optimizing dosing and fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in pediatric patients with tuberculosis: a prospective population pharmacokinetic study. Clin Infect Dis 2021; ciab908
      16. Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama JR, Shenje J, De Los Rios J, Comins K, Morganroth J, Diacon AH, Cramer YS, Donahue K, Maartens G, Alli O, Gottesman J, Guevara M, Hikuam C, Hovind L, Karlsson M, McClaren J, McIlleron H, Murtaugh W, Rolls B, Shahkolahi A, Stone L, Tegha G, Tenai J, Upton C, Wimbish C. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis 2021; 21: 975–83.
      17. Egbelowo O, Sarathy JP, Gausi K, Zimmerman MD, Wang H, Wijnant G-J, Kaya F, Gengenbacher M, Van N, Degefu Y, Nacy C, Aldridge BB, Carter CL, Denti P, Dartois V. Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits. Antimicrob Agents Chemother 2021; 65: e0002421.
      18. Farahani M, Radin E, Saito S, Sachathep KK, Hladik W, Voetsch AC, Auld AF, Balachandra S, Tippett Barr BA, Low A, Smart TF, Musuka G, Jonnalagadda S, Hakim AJ, Wadonda-Kabondo NW, Jahn A, Mugurungi O, Williams DB, Barradas DT, Payne D, Parekh B, Patel H, Wiesner L, Hoos D, Justman JE. Population Viral Load, Viremia, and Recent HIV-1 Infections: Findings From Population-Based HIV Impact Assessments (PHIAs) in Zimbabwe, Malawi, and Zambia. JAIDS J Acquir Immune Defic Syndr 2021; 87: S81–8.
      19. Francis J, Mngqibisa R, McIlleron H, Kendall MA, Wu X, Dooley KE, Firnhaber C, Godfrey C, Cohn SE, Denti P. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug–Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clin Pharmacol Ther 2021; 110: 1057–65.
      20. Garcia-Prats AJ, Svensson EM, Winckler J, Draper HR, Fairlie L, van der Laan LE, Masenya M, Schaaf HS, Wiesner L, Norman J, Aarnoutse RE, Karlsson MO, Denti P, Hesseling AC. Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. J Antimicrob Chemother 2021; 76: 3237–46.
      21. Gausi K, Ignatius EH, Sun X, Kim S, Moran L, Wiesner L, von Groote-Bidlingmaier F, Hafner R, Donahue K, Vanker N, Rosenkranz SL, Swindells S, Diacon AH, Nuermberger EL, Dooley KE, Denti P. A Semimechanistic Model of the Bactericidal Activity of High-Dose Isoniazid against Multidrug-Resistant Tuberculosis: Results from a Randomized Clinical Trial. Am J Respir Crit Care Med 2021; 204: 1327–35.
      22. Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, Chipato T, Haas DW, Browning R, Chakhtoura N, Montepiedra G, Aaron L, McCarthy K, Bradford S, Vhembo T, Stranix-Chibanda L, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Nevrekhar N, Rouzier V, Kabugho E, Mutambanengwe M, Chanaiwa V, Nyati M, Mhembere T, Tongprasert F, Hesseling A, Shin K, Zimmer B, Costello D, Jean-Philippe P, Sterling TR, Theron G, Weinberg A, Gupta A, Denti P, IMPAACT P1078 (TB APPRISE) Study Group Team. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clin Pharmacol Ther 2021; 109: 1034–44.
      23. Gibhard L, Coertzen D, Reader J, van der Watt ME, Birkholtz L-M, Wong HN, Batty KT, Haynes RK, Wiesner L. The Artemiside-Artemisox-Artemisone-M1 Tetrad: Efficacies against Blood Stage P. falciparum Parasites, DMPK Properties, and the Case for Artemiside. Pharmaceutics 2021; 13: 2066.
      24. Gray GE, Bekker L-G, Laher F, Malahleha M, Allen M, Moodie Z, Grunenberg N, Huang Y, Grove D, Prigmore B, Kee JJ, Benkeser D, Hural J, Innes C, Lazarus E, Meintjes G, Naicker N, Kalonji D, Nchabeleng M, Sebe M, Singh N, Kotze P, Kassim S, Dubula T, Naicker V, Brumskine W, Ncayiya CN, Ward AM, Garrett N, Kistnasami G, Gaffoor Z, Selepe P, Makhoba PB, Mathebula MP, Mda P, Adonis T, Mapetla KS, Modibedi B, Philip T, Kobane G, Bentley C, Ramirez S, Takuva S, Jones M, Sikhosana M, Atujuna M, Andrasik M, Hejazi NS, Puren A, Wiesner L, Phogat S, Diaz Granados C, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N, Kublin JG, McElrath MJ, Gilbert PB, Janes H, Corey L. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults. N Engl J Med 2021; 384: 1089–100.
      25. Griesel R, Maartens G, Chirehwa M, Sokhela S, Akpomiemie G, Moorhouse M, Venter F, Sinxadi P. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis 2021; 73: e3902–9.
      26. Ignatius EH, Abdelwahab MT, Hendricks B, Gupte N, Narunsky K, Wiesner L, Barnes G, Dawson R, Dooley KE, Denti P. Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. Antimicrob Agents Chemother 2021; 65: e01196-20.
      27. Kawuma AN, Walimbwa SI, Pillai GC, Khoo S, Lamorde M, Wasmann RE, Denti P. Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine. J Antimicrob Chemother 2021; 76: 1269–72.
      28. Keene CM, Griesel R, Zhao Y, Gcwabe Z, Sayed K, Hill A, Cassidy T, Ngwenya O, Jackson A, van Zyl G, Schutz C, Goliath R, Flowers T, Goemaere E, Wiesner L, Simmons B, Maartens G, Meintjes G. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen. AIDS 2021; 35: 1423–32.
      29. Kipkorir T, Mashabela GT, de Wet TJ, Koch A, Dawes SS, Wiesner L, Mizrahi V, Warner DF. De Novo Cobalamin Biosynthesis, Transport, and Assimilation and Cobalamin-Mediated Regulation of Methionine Biosynthesis in Mycobacterium smegmatis. J Bacteriol 2021; 203. DOI:10.1128/JB.00620-20.
      30. Langaee T, Al-Shaer MH, Gong Y, Lima E, Antwi S, Enimil A, Dompreh A, Yang H, Alghamdi WA, Wiesner L, Peloquin CA, Kwara A. Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection. Infect Genet Evol 2021; 92: 104856.
      31. Leonard MA, Cindi Z, Bradford Y, Bourgi K, Koethe J, Turner M, Norwood J, Woodward B, Erdem H, Basham R, Baker P, Rebeiro PF, Sterling TR, Hulgan T, Daar ES, Gulick R, Riddler SA, Sinxadi P, Ritchie MD, Haas DW. Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. Clin Infect Dis 2021; 73: e2153–63.
      32. Low A, Teasdale C, Brown K, Barradas DT, Mugurungi O, Sachathep K, Nuwagaba-Biribonwoha H, Birhanu S, Banda A, Frederix K, Payne D, Radin E, Wiesner L, Ginindza C, Philip N, Musuka G, Sithole S, Patel H, Maile L, Abrams EJ, Arpadi S. Human Immunodeficiency Virus Infection in Adolescents and Mode of Transmission in Southern Africa: A Multinational Analysis of Population-Based Survey Data. Clin Infect Dis 2021; 73: 594–604.
      33. Malo A, Kellermann T, Ignatius EH, Dooley KE, Dawson R, Joubert A, Norman J, Castel S, Wiesner L. A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients. J Pharm Biomed Anal 2021; 195: 113885.
      34. Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, Norman J, Zhang N, Townley E, Chakhtoura N, Bradford S, Patil S, Popson S, Chipato T, Rouzier V, Langat D, Chalermchockcharoentkit A, Kamthunzi P, Gupta A, Dooley KE. Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. Clin Infect Dis 2021; : 1–12.
      35. Mehta U, Smith M, Kalk E, Hayes H, Swart A, Tucker L, Coetzee R, Boulle A, Blockman M. Understanding and Responding to Prescribing Patterns of Sodium Valproate-Containing Medicines in Pregnant Women and Women of Childbearing Age in Western Cape, South Africa. Drug Saf 2021; 44: 41–51.
      36. Melis DR, Hsiao C-Y, Combrinck JM, Wiesner L, Smith GS. Subcellular Localisation of a Quinoline-Containing Fluorescent Cyclometallated IrIII Complex in Plasmodium falciparum. Chembiochem 2021; 22: 1568–72.
      37. Molomo RN, Basera W, Chetty-Mhlanga S, Fuhrimann S, Mugari M, Wiesner L, Röösli M, Dalvie MA. Relation between organophosphate pesticide metabolite concentrations with pesticide exposures, socio-economic factors and lifestyles: A cross-sectional study among school boys in the rural Western Cape, South Africa. Environ Pollut 2021; 275: 116660.
      38. Moodley K, Blockman M, Pienaar D, Hawkridge AJ, Meintjes J, Davies M-A, London L. Hard choices: Ethical challenges in phase 1 of COVID-19 vaccine roll-out in South Africa. S Afr Med J 2021; 111: 554–8.
      39. Moosa MS, Maartens G, Gunter H, Allie S, Chughlay MF, Setshedi M, Wasserman S, Stead DF, Hickman N, Stewart A, Sonderup M, Spearman CW, Cohen K. A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug–Induced Liver Injury. Clin Infect Dis 2021; 73: e3377–83.
      40. Mouton JP, Blockman M, Sekaggya‐Wiltshire C, Semakula J, Waitt C, Pirmohamed M, Cohen K. Improving anticoagulation in sub‐Saharan Africa: What are the challenges and how can we overcome them? Br J Clin Pharmacol 2021; 87: 3056–68.
      41. Mouton JP, Jobanputra N, Njuguna C, Gunter H, Stewart A, Mehta U, Lahri S, Court R, Igumbor E, Maartens G, Cohen K. Adult medical emergency unit presentations due to adverse drug reactions in a setting of high HIV prevalence. African J Emerg Med 2021; 11: 46–52.
      42. Ngwalero P, Brust JCM, van Beek SW, Wasserman S, Maartens G, Meintjes G, Joubert A, Norman J, Castel S, Gandhi NR, Denti P, McIlleron H, Svensson EM, Wiesner L. Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. Antimicrob Agents Chemother 2021; 65: e0239920.
      43. Owor M, Tierney C, Ziemba L, Browning R, Moye J, Graham B, Reding C, Costello D, Norman J, Wiesner L, Hughes E, Whalen ME, Purdue L, Mmbaga BT, Kamthunzi P, Kawalazira R, Nathoo K, Bradford S, Coletti A, Aweeka F, Musoke P. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092. Pediatr Infect Dis J 2021; 40: 446–52.
      44. Parrish AG, Blockman M, Cohen K, Dawood H, De Waal R, Gray AL, Kredo T, Leong TD, Nel J, Rees H, Reubenson G. Meta-analytic magic, ivermectin, and socially responsible reporting. South African Med J 2021; 111: 934.
      45. Radtke KK, Hesseling AC, Winckler JL, Draper HR, Solans BP, Thee S, Wiesner L, van der Laan LE, Fourie B, Nielsen J, Schaaf HS, Savic RM, Garcia-Prats AJ. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Clin Infect Dis 2021; published online July 21. DOI:10.1093/cid/ciab641.
      46. Rawizza HE, Oladokun R, Ejeliogu E, Oguche S, Ogunbosi BO, Agbaji O, Odaibo G, Imade G, Olaleye D, Wiesner L, Darin KM, Okonkwo P, Kanki PJ, Scarsi KK, McIlleron HM. Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART. J Antimicrob Chemother 2021; 76: 710–7.
      47. Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G, Wilkinson RJ, Ford N, Golub JE, Williams BG, Barnabas R V. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. lancet HIV 2021; 8: e8–15.
      48. Ruffieux Y, Efthimiou O, Van den Heuvel LL, Joska JA, Cornell M, Seedat S, Mouton JP, Prozesky H, Lund C, Maxwell N, Tlali M, Orrell C, Davies M-A, Maartens G, Haas AD. The treatment gap for mental disorders in adults enrolled in HIV treatment programmes in South Africa: a cohort study using linked electronic health records. Epidemiol Psychiatr Sci 2021; 30: e37.
      49. Semakula JR, Kisa G, Mouton JP, Cohen K, Blockman M, Pirmohamed M, Sekaggya-Wiltshire C, Waitt C. Anticoagulation in sub-Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin. Br J Clin Pharmacol 2021; 87: 3699–705.
      50. Seneadza NAH, Antwi S, Yang H, Enimil A, Dompreh A, Wiesner L, Peloquin CA, Lartey M, Lauzardo M, Kwara A. Effect of malnutrition on the pharmacokinetics of anti-TB drugs in Ghanaian children. Int J Tuberc Lung Dis 2021; 25: 36–42.
      51. Sinxadi PZ, Khoo SH, Boffito M. Pharmacokinetic interactions of modern antiretroviral therapy. AIDS 2021; 35: S145–51.
      52. Sjögren E, Tarning J, Barnes KI, Jonsson EN. A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children. Pharmaceutics 2021; 13: 204.
      53. Stek C, Buyze J, Menten J, Schutz C, Thienemann F, Blumenthal L, Maartens G, Boyles T, Wilkinson RJ, Meintjes G, Lynen L. Diagnostic Accuracy of the INSHI Consensus Case Definition for the Diagnosis of Paradoxical Tuberculosis-IRIS. J Acquir Immune Defic Syndr 2021; 86: 587–92.
      54. Stranix-Chibanda L, Anderson PL, Kacanek D, Hosek S, Huang S, Nematadzira TG, Taulo F, Korutaro V, Nakabiito C, Masenya M, Lypen K, Brown E, Ibrahim ME, Yager J, Wiesner L, Johnston B, Amico KR, Rooney JF, Chakhtoura N, Spiegel HML, Chi BH, IMPAACT 2009 Team. Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa. Clin Infect Dis 2021; 73: e1893–900.
      55. Sturkenboom MGG, Märtson A-G, Svensson EM, Sloan DJ, Dooley KE, van den Elsen SHJ, Denti P, Peloquin CA, Aarnoutse RE, Alffenaar J-WC. Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. Clin Pharmacokinet 2021; 60: 685–710.
      56. Tanner L, Mashabela GT, Omollo CC, de Wet TJ, Parkinson CJ, Warner DF, Haynes RK, Wiesner L. Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy. Microbiol Spectr 2021; 9: e0043421.
      57. Thorpe R, Blockman M, Burgess T. Analgesic practices and predictors of use in South Africa-based runners. S Afr Med J 2021; 111: 321–6.
      58. van der Laan LE, Garcia-Prats AJ, Schaaf HS, Winckler JL, Draper H, Norman J, Wiesner L, McIlleron H, Denti P, Hesseling AC. Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. Front Pharmacol 2021; 12: 722204.
      59. van Rensburg R, Nightingale S, Brey N, Albertyn CH, Kellermann TA, Taljaard JJ, Esterhuizen TM, Sinxadi PZ, Decloedt EH. Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS). Clin Infect Dis 2021; published online Nov 19. DOI:10.1093/cid/ciab961.
      60. Walter ND, Born SEM, Robertson GT, Reichlen M, Dide-Agossou C, Ektnitphong VA, Rossmassler K, Ramey ME, Bauman AA, Ozols V, Bearrows SC, Schoolnik G, Dolganov G, Garcia B, Musisi E, Worodria W, Huang L, Davis JL, Nguyen N V., Nguyen H V., Nguyen AT V, Phan H, Wilusz C, Podell BK, Sanoussi ND, de Jong BC, Merle CS, Affolabi D, McIlleron H, Garcia-Cremades M, Maidji E, Eshun-Wilson F, Aguilar-Rodriguez B, Karthikeyan D, Mdluli K, Bansbach C, Lenaerts AJ, Savic RM, Nahid P, Vásquez JJ, Voskuil MI. Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. Nat Commun 2021; 12: 2899.
      61. Wasmann RE, Svensson EM, Walker AS, Clements MN, Denti P. Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children. Br J Clin Pharmacol 2021; 87: 2847–54.
      62. Wasserman S, Davis A, Stek C, Chirehwa M, Botha S, Daroowala R, Bremer M, Maxebengula M, Koekemoer S, Goliath R, Jackson A, Crede T, Naude J, Szymanski P, Vallie Y, Moosa MS, Wiesner L, Black J, Meintjes G, Maartens G, Wilkinson RJ. Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. Antimicrob Agents Chemother 2021; 65: e0014021.
      63. Watson DJ, Laing L, Gibhard L, Wong HN, Haynes RK, Wiesner L. Toward New Transmission-Blocking Combination Therapies: Pharmacokinetics of 10-Amino-Artemisinins and 11-Aza-Artemisinin and Comparison with Dihydroartemisinin and Artemether. Antimicrob Agents Chemother 2021; 65: e0099021.
      64. Watson DJ, Meyers PR, Acquah KS, Dziwornu GA, Barnett CB, Wiesner L. Discovery of Novel Cyclic Ethers with Synergistic Antiplasmodial Activity in Combination with Valinomycin. Molecules 2021; 26. DOI:10.3390/molecules26247494.
      65. Winckler JL, Schaaf HS, Draper HR, McIlleron H, Norman J, van der Laan LE,     Wiesner L, Donald PR, Hesseling AC, Garcia-Prats AJ. Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB. Int J Tuberc Lung Dis 2021; 25: 896–902.

    • 2020

      1. Hibma JE, Radtke KK, Dorman SE, Jindani A, Dooley KE, Weiner M, McIlleron HM, Savic RM. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection. Am J Respir Crit Care Med 2020; 202: 866–77.
      2. Abdelwahab MT, Wasserman S, Brust JCM, Gandhi NR, Meintjes G, Everitt D, Diacon A, Dawson R, Wiesner L, Svensson EM, Maartens G, Denti P. Clofazimine pharmacokinetics in patients with TB: dosing implications. J Antimicrob Chemother 2020; 75: 3269–77.
      3. Alffenaar J-WC, Gumbo T, Dooley KE, Peloquin CA, Mcilleron H, Zagorski A, Cirillo DM, Heysell SK, Silva DR, Migliori GB. Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. Clin Infect Dis 2020; 70: 1774–80.
      4. Anderson SG, McCaul M, Khoo S, Wiesner L, Sacktor N, Joska JA, Decloedt EH. The neurologic phenotype of South African patients with HIV-associated neurocognitive impairment. Neurol Clin Pract 2020; 10: 15–22.
      5. Antel K, Oosthuizen J, Malherbe F, Louw VJ, Nicol MP, Maartens G, Verburgh E. Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. BMC Infect Dis 2020; 20: 33.
      6. Barr DA, Lewis JM, Feasey N, Schutz C, Kerkhoff AD, Jacob ST, Andrews B, Kelly P, Lakhi S, Muchemwa L, Bacha HA, Hadad DJ, Bedell R, van Lettow M, Zachariah R, Crump JA, Alland D, Corbett EL, Gopinath K, Singh S, Griesel R, Maartens G, Mendelson M, Ward AM, Parry CM, Talbot EA, Munseri P, Dorman SE, Martinson N, Shah M, Cain K, Heilig CM, Varma JK, von Gottberg A, Sacks L, Wilson D, Squire SB, Lalloo DG, Davies G, Meintjes G. Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data. Lancet Infect Dis 2020; 20: 742–52
      7. Bell Gorrod H, Court R, Schomaker M, Maartens G, Murphy RA. Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. JAIDS J Acquir Immune Defic Syndr 2020; 84: 107–13.
      8. Boyles TH, Nduna M, Pitsi T, Scott L, Fox MP, Maartens G. A Clinical Prediction Score Including Trial of Antibiotics and C-Reactive Protein to Improve the Diagnosis of Tuberculosis in Ambulatory People With HIV. Open Forum Infect Dis 2020; 7: 543.
      9. Brooke BD, Raman J, Frean J, Rundle J, Maartens F, Misiani E, Mabuza A, Barnes KI, Moonasar DP, Dlamini Q, Charles S, Blumberg L, Rundle K, Maartens F, Misiani E, Mabuza A, Barnes KI, Moonasar DP, Dlamini Q, Charles S, Blumberg L. Implementing malaria control in South Africa, Eswatini and southern Mozambique during the COVID-19 pandemic. S Afr Med J 2020; 110: 1072–6.
      10. Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, McConnell M, Straten A, Baeten JM, Duyver M, Mendel E, Naidoo K, Dallimore J, Wiesner L, Bekker L. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J Int AIDS Soc 2020; 23: e25636.
      11. Chan XHS, Win YN, Haeusler IL, Tan JY, Loganathan S, Saralamba S, Chan SKS, Ashley EA, Barnes KI, Baiden R, Bassi PU, Djimde A, Dorsey G, Duparc S, Hanboonkunupakarn B, ter Kuile FO, Lacerda MVG, Nasa A, Nosten FH, Onyeji CO, Pukrittayakamee S, Siqueira AM, Tarning J, Taylor WRJ, Valentini G, van Vugt M, Wesche D, Day NPJ, Huang CL-H, Brugada J, Price RN, White NJ. Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. PLOS Med 2020; 17: e1003040.
      12. Chirehwa MT, Court R, de Kock M, Wiesner L, de Vries N, Harding J, Gumbo T, Maartens G, Warren R, Denti P, McIlleron H. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. Antimicrob Agents Chemother 2020; 64: e01381-20.
      13. Ebrahim I, Maartens G, Wiesner L, Orrell C, Smythe W, McIlleron H. Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV. J Antimicrob Chemother 2020; 75: 1019–25.
      14. Engelbrecht AE, Wiesner L, Norman J, Rabie H, Decloedt EH. Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital. J Trop Pediatr 2020; 66: 385–94.
      15. Francis J, Barnes KI, Workman L, Kredo T, Vestergaard LS, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I, Sutherland CJ, Merry C, Scarsi KK, Nyagonde N, Lemnge MM, Khoo SH, Bygbjerg IC, Parikh S, Aweeka FT, Tarning J, Denti P. An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. Antimicrob Agents Chemother 2020; 64: e02394-19.
      16. Ghafari N, Court R, Chirehwa MT, Wiesner L, Petersen L, Maartens G, Gumbo T, McIlleron H, Ramma L. Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis. Int J Audiol 2020; 59: 219–23.
      17. Gill K, Johnson L, Dietrich J, Myer L, Marcus R, Wallace M, Pidwell T, Mendel E, Fynn L, Jones K, Wiesner L, Slack C, Strode A, Spiegel H, Hosek S, Rooney J, Gray G, Bekker L-G. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial. Lancet Child Adolesc Heal 2020; 4: 875–83.
      18. Ignatius EH, Abdelwahab MT, Hendricks B, Gupte N, Narunsky K, Wiesner L, Barnes G, Dawson R, Dooley KE, Denti P. Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis. Antimicrob Agents Chemother 2020; 65: e01196-20.
      19. Jacobs TG, Svensson EM, Musiime V, Rojo P, Dooley KE, McIlleron H, Aarnoutse RE, Burger DM, Turkova A, Colbers A, Abrams E, Archary M, Belew Y, Best B, Burger D, Burry J, Capparelli E, Carpenter D, Casas E, Clayden P, Clarke D, Cressey T, Colbers A, Dangarembizi M, Denti P, Diop K, Ecker A, Essajee S, Giaquinto C, Gibb D, Hazra R, Kim M, Lallemant M, Lee J, Lewis L, Lockman S, Mirochnick M, Mofenson L, Musiime V, Obimbo E, Ojoo A, Pascual F, Penazzato M, Pinto J, Rakhmanina N, Rojo P, Ruel T, Siberry G, Sugandhi N, Turkova A, Vicari M, Watkins M, Wolf H. Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. J Antimicrob Chemother 2020; 75: 3433–57.
      20. Jones J, Swart A, Tommy E, Cohen K, Stewart A, Voget J, Blockman M. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa. S Afr Med J 2020; 110: 1226-30.
      21. Kalk E, Heekes A, Mehta U, de Waal R, Jacob N, Cohen K, Myer L, Davies M-A, Maartens G, Boulle A. Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data. Clin Infect Dis 2020; 71: e351–8.
      22. Labuschaigne M, Slabbert M, Budree S, Hoosien E, Brink A, Blockman M. The ethicolegal framework relevant to human faecal microbiota transplants in South Africa: Part 1. A legal vacuum. S Afr Med J 2020; 110: 812–5.
      23. Maartens G, Griesel R, Dube F, Nicol M, Mendelson M. Etiology of Pulmonary Infections in Human Immunodeficiency Virus-infected Inpatients Using Sputum Multiplex Real-time Polymerase Chain Reaction. Clin Infect Dis 2020; 70: 1147–52.
      24. McGready R, Nosten F, Barnes KI, Mokuolu O, White NJ. Why is WHO failing women with falciparum malaria in the first trimester of pregnancy? Lancet 2020; 395: 779.
      25. Melis DR, Barnett CB, Wiesner L, Nordlander E, Smith GS. Quinoline-triazole half-sandwich iridium(III) complexes: synthesis, antiplasmodial activity and preliminary transfer hydrogenation studies. Dalt Trans 2020; 49: 11543–55.
      26. Mngqibisa R, Kendall MA, Dooley K, Wu X (Shirley), Firnhaber C, Mcilleron H, Robinson J, Cramer Y, Rosenkranz SL, Roa J, Coughlin K, Mawlana S, Badal-Faesen S, Schnabel D, Omoz-Oarhe A, Samaneka W, Godfrey C, Cohn SE. Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. Clin Infect Dis 2020; 71: 517–24.
      27. Morrell R, Barnes K, Gumedze F, Sadiq H, Price M. Misrepresentation of research on academic promotions at the University of Cape Town. Cogent Soc Sci 2020; 6: 1728949.
      28. Mthiyane T, Millard J, Adamson J, Balakrishna Y, Connolly C, Owen A, Rustomjee R, Dheda K, McIlleron H, Pym AS. N -Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N -Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment. Antimicrob Agents Chemother 2020; 64: e02376-19.
      29. Nabisere R, Musaazi J, Denti P, Aber F, Lamorde M, Dooley KE, Aarnoutse R, Sloan DJ, Sekaggya-Wiltshire C. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials 2020; 21: 181.
      30. Nyberg HB, Draper HR, Garcia-Prats AJ, Thee S, Bekker A, Zar HJ, Hooker AC, Simon Schaaf H, McIlleron H, Hesseling AC, Denti P. Population pharmacokinetics and dosing of ethionamide in children with tuberculosis. Antimicrob Agents Chemother 2020; 64: 1–12.
      31. Rabie H, Tikiso T, Lee J, Fairlie L, Strehlau R, Bobat R, Liberty A, McIlleron H, Andrieux-Meyer I, Cotton M, Lallemant M, Denti P. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Antimicrob Agents Chemother 2020; 64: e01923-19.
      32. Rajpurkar P, O’Connell C, Schechter A, Asnani N, Li J, Kiani A, Ball RL, Mendelson M, Maartens G, van Hoving DJ, Griesel R, Ng AY, Boyles TH, Lungren MP. CheXaid: deep learning assistance for physician diagnosis of tuberculosis using chest x-rays in patients with HIV. npj Digit Med 2020; 3: 115.
      33. Raman J, Barnes KI, Baker L, Blaylock M, Blumberg L, Frean J, Misiani E, Ukpe IS. Maintaining focus on administering effective malaria treatment during the COVID-19 pandemic. S Afr Med J 2020; 111: 13-16.
      34. Schutz C, Chirehwa M, Barr D, Ward A, Janssen S, Burton R, Wilkinson RJ, Shey M, Wiesner L, Denti P, McIlleron H, Maartens G, Meintjes G. Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis. Br J Clin Pharmacol 2020; 86: 966–78.
      35. Sinxadi P, Donini C, Johnstone H, Langdon G, Wiesner L, Allen E, Duparc S, Chalon S, McCarthy JS, Lorch U, Chibale K, Möhrle J, Barnes KI. Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers. Antimicrob Agents Chemother 2020; 64: e01896-19.
      36. Stepniewska K, Humphreys GS, Gonçalves BP, Craig E, Gosling R, Guerin PJ, Price RN, Barnes KI, Raman J, Smit MR, D’Alessandro U, Stone WJR, Bjorkman A, Samuels AM, Arroyo-Arroyo MI, Bastiaens GJH, Brown JM, Dicko A, El-Sayed BB, Elzaki S-EG, Eziefula AC, Kariuki S, Kwambai TK, Maestre AE, Martensson A, Mosha D, Mwaiswelo RO, Ngasala BE, Okebe J, Roh ME, Sawa P, Tiono AB, Chen I, Drakeley CJ, Bousema T. Efficacy of Single-Dose Primaquine With Artemisinin Combination Therapy on Plasmodium falciparum Gametocytes and Transmission: An Individual Patient Meta-Analysis. J Infect Dis 2020; 4: 1–12.
      37. Strydom N, Kaur G, Dziwornu GA, Okombo J, Wiesner L, Chibale K. Pharmacokinetics and Organ Distribution of C-3 Alkyl Esters as Potential Antimycobacterial Prodrugs of Fusidic Acid. ACS Infect Dis 2020; 6: 459–66.
      38. Sykes W, Van Den Berg K, Jacobs G, Jauregui A, Roubinian N, Wiesner L, Maartens G, Swanevelder R, Custer B, Busch M, Jentsch U, Murphy EL, Vermeulen M. Discovery of False Elite Controllers: HIV Antibody-Positive RNA-Negative Blood Donors Found to Be on Antiretroviral Therapy. J Infect Dis 2020; 221: 643–7.
      39. Tanner L, Haynes RK, Wiesner L. Accumulation of TB-Active Compounds in Murine Organs Relevant to Infection by Mycobacterium tuberculosis. Front Pharmacol 2020; 11: 1–8.
      40. Van Hoving DJ, Kenge AP, Maartens G, Meintjes G. Point-of-Care Ultrasound Predictors for the Diagnosis of Tuberculosis in HIV-Positive Patients Presenting to an Emergency Center. JAIDS J Acquir Immune Defic Syndr 2020; 83: 415–23.
      41. Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV 2020; 7: e666–76.
      42. Wasserman S, Huo S, Ky K, Malig YN, Esmail A, Dheda K, Bacchetti P, Gerona R, Maartens G, Gandhi M, Metcalfe J. Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis. Antimicrob Agents Chemother 2020; 64: 1–8.
      43. Wearne N, Davidson B, Blockman M, Swart A, Jones ES. HIV, drugs and the kidney. Drugs Context 2020; 9: 1–17.
      44. Wong HN, Padín-Irizarry V, van der Watt ME, Reader J, Liebenberg W, Wiesner L, Smith P, Eribez K, Winzeler EA, Kyle DE, Birkholtz L-M, Coertzen D, Haynes RK. Optimal 10-Aminoartemisinins With Potent Transmission-Blocking Capabilities for New Artemisinin Combination Therapies–Activities Against Blood Stage P. falciparum Including PfKI3 C580Y Mutants and Liver Stage P. berghei Parasites. Front Chem 2020; 7: 1–16.
      45. De Vries J, Burgess T, Blockman M, Ntusi NAB. Research on COVID-19 in South Africa: Guiding principles for informed consent. S Afr Med J 2020; 110: 635–9.
      46. Decloedt EH, Reuter H, Allwood B, Parker A, Koegelenberg CFN, Blockman M, Taljaard J. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease. S Afr Med J 2020; 110: 336.
      47. Mouton JP, Fortuin-de Smidt MC, Jobanputra N, Mehta U, Stewart A, de Waal R, Technau KG, Argent A, Kroon M, Scott C, Cohen K. Serious adverse drug reactions at two children's hospitals in South Africa. BMC Pediatr 2020; 20: 3.
      48. Semakula JR, Mouton JP, Jorgensen A, Hutchinson C, Allie S, Semakula L, French N, Lamorde M, Toh CH, Blockman M, Sekaggya-Wiltshire C, Waitt C, Pirmohamed M, Cohen K. A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. PLoS One 2020; 15: e0227458.
      49. Cerrone M, Bracchi M, Wasserman S, Pozniak A, Meintjes G, Cohen K, Wilkinson RJ. Safety implications of combined antiretroviral and anti-tuberculosis drugs. Expert Opin Drug Saf 2020; 19: 23-41.
      50. Kariuki SM, Selhorst P, Norman J, Cohen K, Rebe K, Williamson C, Dorfman JR. Detectable HIV-1 in semen in individuals with very low blood viral loads. Virology Journal 2020; 17: 5.

    • 2019

      1. Alghamdi WA, Antwi S, Enimil A, Yang H, Dompreh A, Wiesner L, Langaee T, Peloquin CA, Kwara A. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing. J Antimicrob Chemother 2019; 74: 2698–2706.
      2. Antel K, Levetan C, Mohamed Z, Louw VJ, Oosthuizen J, Maartens G, Verburgh E. The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting. BMC Cancer 2019; 19: 384.
      3. Archary M, Mcllleron H, Bobat R, LaRussa P, Sibaya T, Wiesner L, Hennig S. Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes. Br J Clin Pharmacol 2019; 85: 2066–2075.
      4. Banda CG, Barnes KI, Maartens G. Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. Antimicrob Agents Chemother 2019; 63: e00576-19.
      5. Barnes KI, Canario JA, Vernekar SS, Goudar SS, Espinal R, Merson L, Cheah PY. Equitable data sharing: challenges and suggestions for ways forward. Wellcome Open Res 2019; 4: 172.
      6. Baughman RP, Culver DA, Cordova FC, Padilla M, Gibson KF, Lower EE, Engel PJ. Bosentan for sarcoidosis-associated pulmonary hypertension: A double-blind placebo controlled randomized trial. Chest 2014; 145: 810–817.
      7. Bjugård Nyberg H, Draper HR, Garcia-Prats AJ, Thee S, Bekker A, Zar HJ, Hooker AC, Schaaf HS, McIlleron H, Hesseling AC, Denti P. Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. Antimicrob Agents Chemother 2019; 64: 1–12.
      8. Bleloch JS, du Toit A, Gibhard L, Kimani S, Ballim RD, Lee M, Blanckenberg A, Mapolie S, Wiesner L, Loos B, Prince S. The palladacycle complex AJ-5 induces apoptotic cell death while reducing autophagic flux in rhabdomyosarcoma cells. Cell death Discov 2019; 5: 60.
      9. Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, Maartens G, Pozniak A, Flexner C, Boffito M. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. J Antimicrob Chemother 2019; 74: 1670–8.
      10. Chirehwa MT, McIlleron H, Wiesner L, Affolabi D, Bah-Sow O, Merle C, Denti P, RAFA team. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. J Antimicrob Chemother 2019; 74: 139–148.
      11. Chirehwa MT, Velásquez GE, Gumbo T, McIlleron H. Quantitative assessment of the activity of antituberculosis drugs and regimens. Expert Rev Anti Infect Ther 2019; 17: 449–457.
      12. Chotsiri P, Denoeud-Ndam L, Baudin E, Guindo O, Diawara H, Attaher O, Smit M, Guerin PJ, Doumbo OK, Wiesner L, Barnes KI, Hoglund RM, Dicko A, Etard J-FFJ, Tarning J, Denoeud‐Ndam L, Baudin E, Guindo O, Diawara H, Attaher O, Smit M, Guerin PJ, Doumbo OK, Wiesner L, Barnes KI, Hoglund RM, Dicko A, Etard J-FFJ, Tarning J, Denoeud-Ndam L, Baudin E, Guindo O, Diawara H, Attaher O, Smit M, Guerin PJ, Doumbo OK, Wiesner L, Barnes KI, Hoglund RM, Dicko A, Etard J-FFJ, Tarning J. Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. Clin Pharmacol Ther 2019; 106: 1299–1309.
      13. Cohen K, Maartens G. A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis. Expert Opin Drug Saf 2019; 18: 875–882.
      14. Cohen K, Orrell CJ. Transition to third-line ART in resource-limited settings. lancet HIV 2019; 6: e725–727.
      15. Cohen K, Stewart A, Kengne AP, Leisegang R, Coetsee M, Maharaj S, Dunn L, Hislop M, van Zyl G, Meintjes G, Maartens G. A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy. J Acquir Immune Defic Syndr 2019; 80: 325–329.
      16. Cohn SE, Park J-G, Watts DH, Stek A, Hitti J, Clax PA, Yu S, Hall SD. Depo-medroxyprogesterone in Women on Antiretroviral Therapy: Effective Contraception and Lack of Clinically Significant Interactions. Clin Pharmacol Ther   2007; 81: 222–227.
      17. Court R, Chirehwa MT, Wiesner L, de Vries N, Harding J, Gumbo T, Maartens G, McIlleron H. Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2019; 23: 1068–1074.
      18. Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, Touw DJ, Andersen AB, Bekker A, Denti P, Hemanth Kumar AK, Jeremiah K, Kwara A, McIlleron H, Meintjes G, van Oosterhout JJ, Ramachandran G, Rockwood N, Wilkinson RJ, van der Werf TS, Alffenaar J-WC. A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. Clin Pharmacokinet 2019; 58: 747–766.
      19. Decloedt EH, Sinxadi PZ, van Zyl GU, Wiesner L, Khoo S, Joska JA, Haas DW, Maartens G. Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites. J Antimicrob Chemother 2019; 74: 699–709.
      20. Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM, Esmail A, Nardell E, London L, Lessem E, Limberis J, Theron G, McNerney R, Niemann S, Dowdy D, Van Rie A, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Schaaf HS, Chang KC, Lange C, Nahid P, Fourie B, Ndjeka N, Nunn A, Migliori GB, Udwadia ZF, Horsburgh CR, Churchyard GJ, Menzies D, Hesseling AC, Seddon JA, Low M, Keshavjee S, Nuermberger E, McIlleron H, Fennelly KP, Jindani A, Jaramillo E, Padayatchi N, Barry CE. The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respir. Med. 2019; 7: 820–826.
      21. Engelbrecht AE, Wiesner L, Norman J, Rabie H, Decloedt EH. Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital. J Trop Pediatr 2019; 4: 385–394.
      22. Enimil A, Antwi S, Yang H, Dompreh A, Alghamdi WA, Gillani FS, Orstin A, Bosomtwe D, Opoku T, Norman J, Wiesner L, Langaee T, Peloquin CA, Court MH, Greenblatt DJ, Kwara A. Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old. Antimicrob Agents Chemother 2019; 63: e00839-19.
      23. Francis J, Zvada SP, Denti P, Hatherill M, Charalambous S, Mungofa S, Dawson R, Dorman S, Gupte N, Wiesner L, Jindani A, Harrison TS, Olagunju A, Egan D, Owen A, McIlleron HM. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrob Agents Chemother 2019; 63: 1–8.
      24. Garcia-Prats AJ, Schaaf HS, Draper HR, Garcia-Cremades M, Winckler J, Wiesner L, Hesseling AC, Savic RM. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies. PLoS Med 2019; 16: 1–20.
      25. Garcia-Prats AJ, Purchase SE, Osman M, Draper HR, Schaaf HS, Wiesner L, Denti P, Hesseling AC. Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure. Antimicrob Agents Chemother 2019; 63: 1–7.
      26. Griesel R, Cohen K, Mendelson M, Maartens G. Abdominal Ultrasound for the Diagnosis of Tuberculosis Among Human Immunodeficiency Virus-Positive Inpatients With World Health Organization Danger Signs. Open forum Infect Dis 2019; 6: ofz094.
      27. Humphreys GS, Tinto H, Barnes KI. Strength in Numbers: The WWARN Case Study of Purpose-Driven Data Sharing. Am J Trop Med Hyg 2019; 100: 13–15.
      28. Johnston J, Wiesner L, Smith P, Maartens G, Orrell C. Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans. South Afr J HIV Med 2019; 20: 881.
      29. Jones J, Mudaly V, Voget J, Naledi T, Maartens G, Cohen K. Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases. BMC Infect Dis 2019; 19: 544.
      30. Kendall EA, Azman AS, Maartens G, Boulle A, Wilkinson RJ, Dowdy DW, Rangaka MX. Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. AIDS 2019; 33: 525–536.
      31. Lesosky M, Rangaka MX, Pienaar C, Coussens AK, Goliath R, Mathee S, Mwansa-Kambafwile J, Maartens G, Wilkinson RJ, Wilkinson KA. Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus-1. Clin Infect Dis 2019; 69: 295–305.
      32. Manickchund N, du Plessis C, John MAA, Manzini TC, Gosnell BI, Lessells RJ, Moosa YS. Emtricitabine-induced pure red cell aplasia. South Afr J HIV Med 2019; 20: 2078-6751.
      33. Manne-Goehler J, Rohr J, Montana L, Siedner M, Harling G, Gómez-Olivé FX, Geldsetzer P, Wagner R, Wiesner L, Kahn K, Tollman S, Bärnighausen TW. ART Denial: Results of a Home-Based Study to Validate Self-reported Antiretroviral Use in Rural South Africa. AIDS Behav 2019; 23: 2072–2078.
      34. McIlleron H, Chirehwa MT. Current research toward optimizing dosing of first-line antituberculosis treatment. Expert Rev Anti Infect Ther 2019; 17: 27–38.
      35. Meintjes G, Brust JCM, Nuttall J, Maartens G. Management of active tuberculosis in adults with HIV. Lancet HIV 2019; 6: e463–74.
      36. Mngqibisa R, Kendall MA, Dooley K, Wu X (Shirley), Firnhaber C, Mcilleron H, Robinson J, Cramer Y, Rosenkranz SL, Roa J, Coughlin K, Mawlana S, Badal-Faesen S, Schnabel D, Omoz-Oarhe A, Samaneka W, Godfrey C, Cohn SE. Pharmacokinetics and Pharmacodynamics of Depot Medroxyprogesterone Acetate in African Women Receiving Treatment for Human Immunodeficiency Virus and Tuberculosis: Potential Concern for Standard Dosing Frequency. Clin Infect Dis 2019; 6: 517–524.
      37. Moorhouse M, Maartens G, Venter WDF, Moosa M-YY, Steegen K, Jamaloodien K, Fox MP, Conradie F. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes. J Acquir Immune Defic Syndr 2019; 80: 73–8.
      38. efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF). Trials 2020; 21: 181.
      39. Naidoo A, Chirehwa M, Ramsuran V, McIlleron H, Naidoo K, Yende-Zuma N, Singh R, Ncgapu S, Adamson J, Govender K, Denti P, Padayatchi N. Effects of
      40. Phillips TK, Sinxadi P, Abrams EJ, Zerbe A, Orrell C, Hu N-C, Brittain K, Gomba Y, Norman J, Wiesner L, Myer L, Maartens G. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women. J Acquir Immune Defic Syndr 2019; 81: 311–8.
      41. Rabie H, Denti P, Lee J, Masango M, Coovadia A, Pillay S, Liberty A, Simon F, McIlleron H, Cotton MF, Lallemant M. Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study. Lancet HIV 2019; 6: e32–42.
      42. Rabie H, Rawizza H, Zuidewind P, Winckler J, Zar H, Van Rie A, Wiesner L, McIlleron H. Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin. J Antimicrob Chemother 2019; 74: 2347–2351.
      43. Raman J, Allen E, Workman L, Mabuza A, Swanepoel H, Malatje G, Frean J, Wiesner L, Barnes KI. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: An open-label, randomized controlled trial. Malar J 2019; 18: 209.
      44. Raman J, Kagoro FM, Mabuza A, Malatje G, Reid A, Frean J, Barnes KI. Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine-tolerance molecular markers following 18 years of artemisinin-based combination therapy use in Mpumalanga Province, South Africa (2001-2018). Malar J 2019; 18: 280.
      45. Rylands L iqa, Welsh A, Maepa K, Stringer T, Taylor D, Chibale K, Smith GS. Structure-activity relationship studies of antiplasmodial cyclometallated ruthenium(II), rhodium(III) and iridium(III) complexes of 2-phenylbenzimidazoles. Eur J Med Chem 2019; 161: 11–21.
      46. Sadiq H, Barnes KI, Price M, Gumedze F, Morrell RG. Academic promotions at a South African university: questions of bias, politics and transformation. Higher Education 2019; 78: 423–42.
      47. Schutz C, Barr D, Andrade BB, Shey M, Ward A, Janssen S, Burton R, Wilkinson KA, Sossen B, Fukutani KF, Nicol M, Maartens G, Wilkinson RJ, Meintjes G. Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study. PLoS Med 2019; 16: 1–30.
      48. Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, Von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, Calcagno A, Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P. Low antituberculosis drug concentrations in HIV-tuberculosis-coinfected adults with low body weight: Is it time to update dosing guidelines? Antimicrob Agents Chemother 2019; 63: 1–11.
      49. Shenje J, Gumbo T, Wiesner L, Ntsekhe M, Mayosi B, Ross I. Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. IJC Hear Vasc 2019; 22: 105–110.
      50. Stringer T, Quintero MAS, Wiesner L, Smith GS, Nordlander E. Evaluation of PTA-derived ruthenium(II) and iridium(III) quinoline complexes against chloroquine-sensitive and resistant strains of the Plasmodium falciparum malaria parasite. J Inorg Biochem 2019; 191: 164–73.
      51. Stringer T, Wiesner L, Smith GS. Ferroquine-derived polyamines that target resistant Plasmodium falciparum. Eur J Med Chem 2019; 179: 78–83.
      52. Sykes W, Van den Berg K, Jacobs G, Jauregui A, Roubinian N, Wiesner L, Maartens G, Swanevelder R, Custer B, Busch M, Jentsch U, Murphy EL, Vermeulen M, NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Discovery of False Elite Controllers: HIV Antibody-Positive RNA-Negative Blood Donors Found To Be on Antiretroviral Therapy. J Infect Dis 2019; 220: 643–647.
      53. Tanner L, Evans JC, Seldon R, Jordaan A, Warner DF, Haynes RK, Parkinson CJ, Wiesner L. In Vitro Efficacies, ADME, and Pharmacokinetic Properties of Phenoxazine Derivatives Active against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2019; 63: e01010-19.
      54. Tanner L, Haynes RK, Wiesner L. An in vitro ADME and in vivo Pharmacokinetic Study of Novel TB-Active Decoquinate Derivatives. Front Pharmacol 2019; 10: 120.
      55. Tripathi M, Taylor D, Khan SI, Tekwani BL, Ponnan P, Das US, Velpandian T, Rawat DS. Hybridization of Fluoro-amodiaquine (FAQ) with Pyrimidines: Synthesis and Antimalarial Efficacy of FAQ-Pyrimidines. ACS Med Chem Lett 2019; 10: 714–719.
      56. Venter WDF, Moorhouse M, Sokhela S, Serenata C, Akpomiemie G, Qavi A, Mashabane N, Arulappan N, Sim JW, Sinxadi PZ, Wiesner L, Maharaj E, Wallis C, Boyles T, Ripin D, Stacey S, Chitauri G, Hill A. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. lancet HIV 2019; 6: e428–e437.
      57. Wang X, Cerrone M, Ferretti F, Castrillo N, Maartens G, McClure M, Boffito M. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. Int J Antimicrob Agents 2019; 54: 202–206.
      58. Wasserman S, Denti P, Brust JCM, Abdelwahab M, Hlungulu S, Wiesner L, Norman J, Sirgel FA, Warren RM, Esmail A, Dheda K, Gandhi NR, Meintjes G, Maartens G. Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection. Antimicrob Agents Chemother 2019; 63: 1–10.
      59. Wasserman S, Louw G, Ramangoaela L, Barber G, Hayes C, Omar SV, Maartens G,Barry C, Song T, Meintjes G. Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa. J Antimicrob Chemother 2019; 74: 2377–2384.

    • 2018

      1. Ali, A. M., Penny, M. A., Smith, T. A., Workman, L., Sasi, P., Adjei, G. O., Aweeka, F., Kiechel, J. R., Jullien, V., Rijken, M. J., McGready, R., Mwesigwa, J., Kristensen, K., Stepniewska, K., Tarning, J., Barnes, K. I., & Denti, P. (2018). Population pharmacokinetics of the antimalarial amodiaquine: A pooled analysis to optimize dosing. Antimicrobial Agents and Chemotherapy, 62(10), 1–18. https://doi.org/10.1128/AAC.02193-17
      2. Allen, E. N., Chandler, C. I., Mandimika, N., Leisegang, C., & Barnes, K. (2018). Eliciting adverse effects data from participants in clinical trials. Cochrane Database of Systematic Reviews, 2013(5). https://doi.org/10.1002/14651858.MR000039.pub2
      3. Boyles, T. H., Griesel, R., Stewart, A., Mendelson, M., & Maartens, G. (2018). Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV. International Journal of Infectious Diseases, 75, 67–73. https://doi.org/10.1016/j.ijid.2018.08.005
      4. Brunschwig, C., Lawrence, N., Taylor, D., Abay, E., Njoroge, M., Basarab, G. S., Le Manach, C., Paquet, T., Cabrera, D. G., Nchinda, A. T., De Kock, C., Wiesner, L., Denti, P., Waterson, D., Blasco, B., Leroy, D., Witty, M. J., Donini, C., Duffy, J., Wittlin, S., White, K. L., Charman, S. A., Jiménez-Díaz, M. B., Angulo-Barturen, I., Herreros, E., Gamo, F. J., Rochford, R., Mancama, D., Coetzer, T. L., Van der Watt, M. E., Reader, J., Birkholtz, L. M., Marsh, K. C., Solapure, S. M., Burke, J. E., McPhail, J. A., Vanaerschot, M., Fidock, D. A., Fish, P. V., Siegl, P., Smith, D. A., Wirjanata, G., Noviyanti, R., Price, R. N., Marfurt, J., Silue, K. D., Street, L. J., & Chibaleb, K. (2018). Uct943, a next-generation plasmodium falciparum pi4k inhibitor preclinical candidate for the treatment of malaria. Antimicrobial Agents and Chemotherapy, 62(11), AAC.00012-18. https://doi.org/10.1128/AAC.00012-18
      5. Chabala, C., Turkova, A., Thomason, M. J., Wobudeya, E., Hissar, S., Mave, V., van der Zalm, M., Palmer, M., Kapasa, M., Bhavani, P. K., Balaji, S., Raichur, P. A., Demers, A. M., Hoddinott, G., Owen-Powell, E., Kinikar, A., Musoke, P., Mulenga, V., Aarnoutse, R., McIlleron, H., Hesseling, A., Crook, A. M., Cotton, M., & Gibb, D. M. (2018). Shorter treatment for minimal tuberculosis (TB) in children (SHINE): A study protocol for a randomised controlled trial. Trials, 19(1), 237. https://doi.org/10.1186/s13063-018-2608-5
      6. Chirehwa, M. T., McIlleron, H., Wiesner, L., Affolabi, D., Bah-Sow, O., Merle, C., Denti, P., N’Diaye, A., Mbaye, I. M., De Jong, B., Anagonou, S., Diatema, S., Gomina, I. K., Gossa, S., Tanimomo, B., Bekou, W., Galperine, T., Furco, A., Diallo, M., Bah, B., Bah, F., Barry, N., Barry, A., Barry, S., Barry, M. T., Sylla, A. B., Barry, A. M., Sarr, M., Ngom, N. F., Ndiaye, K., Sakho, D., Ngom, J., Ba, F., Seck, A., Furco, A., Floyd, S., Branson, K., Glynn, J., Phillips, D., Oubaya, N., & Saint-Martin, C. (2018). Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. Journal of Antimicrobial Chemotherapy, 74(1), 139–148. https://doi.org/10.1093/jac/dky378
      7. Coertzen, D., Reader, J., Van Der Watt, M., Nondaba, S. H., Gibhard, L., Wiesner, L., Smith, P., D’Alessandro, S., Taramelli, D., Wong, H. N., Du Preez, J. L., Wu, R. W. K., Birkholtz, L. M., & Haynes, R. K. (2018). Artemisone and artemiside are potent panreactive antimalarial agents that also synergize redox imbalance in plasmodium falciparum transmissible gametocyte stages. Antimicrobial Agents and Chemotherapy, 62(8), 1–17. https://doi.org/10.1128/AAC.02214-17
      8. Court, R., Chirehwa, M. T., Wiesner, L., Wright, B., Smythe, W., Kramer, N., & McIlleron, H. (2018). Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. The International Journal of Tuberculosis and Lung Disease, 22(5), 537–543. https://doi.org/10.5588/ijtld.17.0697
      9. Court, R., Wiesner, L., Stewart, A., de Vries, N., Harding, J., Maartens, G., Gumbo, T., & McIlleron, H. (2018). Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease, 22(1), 30–33. https://doi.org/10.5588/ijtld.17.0475
      10. Das, D., Grais, R. F., Okiro, E. A., Stepniewska, K., Mansoor, R., Van Der Kam, S., Terlouw, D. J., Tarning, J., Barnes, K. I., & Guerin, P. J. (2018). Complex interactions between malaria and malnutrition: A systematic literature review. BMC Medicine, 16(1), 186. https://doi.org/10.1186/s12916-018-1177-5
      11. Davlantes, E., Dimbu, P. R., Ferreira, C. M., Florinda Joao, M., Pode, D., Félix, J., Sanhangala, E., Andrade, B. N., Dos Santos Souza, S., Talundzic, E., Udhayakumar, V., Owens, C., Mbounga, E., Wiesner, L., Halsey, E. S., Martins, J. F., Fortes, F., & Plucinski, M. M. (2018). Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. Malaria Journal, 17(1), 144. https://doi.org/10.1186/s12936-018-2290-9
      12. de Kock, M., Tarning, J., Workman, L., Allen, E. N., Tekete, M. M., Djimde, A. A., Bell, D. J., Ward, S. A., Barnes, K. I., & Dentia, P. (2018). Population pharmacokinetic properties of sulfadoxine and pyrimethamine: A pooled analysis to inform optimal dosing in african children with uncomplicated malaria. Antimicrobial Agents and Chemotherapy, 62(5), 1–16. https://doi.org/10.1128/AAC.01370-17
      13. de Waal, R., Cohen, K., Boulle, A., Fox, M. P., Maartens, G., Igumbor, E. U., & Davies, M. A. (2018). Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts. PLoS ONE, 13(9), e0203530. https://doi.org/10.1371/journal.pone.0203530
      14. Deshpande, D., Alffenaar, J.-W. C., Köser, C. U., Dheda, K., Chapagain, M. L., Simbar, N., Schön, T., Sturkenboom, M. G. G., McIlleron, H., Lee, P. S., Koeuth, T., Mpagama, S. G., Banu, S., Foongladda, S., Ogarkov, O., Pholwat, S., Houpt, E. R., Heysell, S. K., & Gumbo, T. (2018). p-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. Clinical Infectious Diseases, 67(suppl_3), S308–S316. https://doi.org/10.1093/cid/ciy624
      15. Deshpande, D., Pasipanodya, J. G., Srivastava, S., Bendet, P., Koeuth, K., Bhavnani, S. M., Ambrose, P. G., Smythe, W., & McIlleron, H. (2018). Gatifloxacin pharmacokinetics/pharmacodynamics-based optimal dosing for pulmonary and meningeal multidrug-resistant tuberculosis. Clinical Infectious Diseases, 67(suppl_3), S274–S283. https://doi.org/10.1093/cid/ciy618
      16. Ebrahim, I., Bryer, A., Cohen, K., Mouton, J. P., Msemburi, W., & Blockman, M. (2018). Poor anticoagulation control in patients taking warfarin at a tertiary and district-level prothrombin clinic in Cape Town, South Africa. South African Medical Journal, 108(6), 490. https://doi.org/10.7196/SAMJ.2018.v108i6.13062
      17. Garcia-Prats, A. J., Rose, P. C., Draper, H. R., Seddon, J. A., Norman, J., McIlleron, H. M., Hesseling, A. C., & Schaaf, H. S. (2018). Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. The Pediatric Infectious Disease Journal, 37(12), 1199–1203. https://doi.org/10.1097/INF.0000000000001983
      18. Gasson, J., Blockman, M., & Willems, B. (2018). Antibiotic prescribing practice and adherence to guidelines in primary care in the Cape Town Metro District, South Africa. South African Medical Journal, 108(4), 304. https://doi.org/10.7196/SAMJ.2018.v108i4.12564
      19. Gibhard, L., Njoroge, M., Paquet, T., Brunschwig, C., Taylor, D., Lawrence, N., Abay, E., Wittlin, S., Wiesner, L., Street, L. J., Chibale, K., & Basarab, G. S. (2018). Investigating sulfoxide to sulfone conversion as a prodrug strategy for a PI4K inhibitor in a humanized mouse model of malaria. Antimicrobial Agents and Chemotherapy, 62(12), 1–11. https://doi.org/10.1128/AAC.00261-18
      20. Griesel, R., Stewart, A., van der Plas, H., Sikhondze, W., Mendelson, M., & Maartens, G. (2018). Prognostic indicators in the World Health Organization’s algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis. AIDS Research and Therapy, 15(1), 5. https://doi.org/10.1186/s12981-018-0192-0
      21. Griesel, R., Stewart, A., van der Plas, H., Sikhondze, W., Rangaka, M. X., Nicol, M. P., Kengne, A. P., Mendelson, M., & Maartens, G. (2018). Optimizing Tuberculosis Diagnosis in Human Immunodeficiency Virus–Infected Inpatients Meeting the Criteria of Seriously Ill in the World Health Organization Algorithm. Clinical Infectious Diseases, 66(9), 1419–1426. https://doi.org/10.1093/cid/cix988
      22. Havenga, K., Abay, E., Wiesner, L., Viljoen, A., Steyn, D., & Hamman, J. (2018). The in Vitro and in Vivo Effects of Hypoxis hemerocallidea on Indinavir Pharmacokinetics: Modulation of Efflux. Planta Medica, 84(12–13), 895–901. https://doi.org/10.1055/a-0607-2743
      23. Horita, Y., Alsultan, A., Kwara, A., Antwi, S., Enimil, A., Ortsin, A., Dompreh, A., Yang, H., Wiesner, L., & Peloquin, C. A. (2018). Evaluation of the adequacy of WHO revised dosages of the first-line antituberculosis drugs in children with tuberculosis using population pharmacokinetic modeling and simulations. Antimicrobial Agents and Chemotherapy, 62(9), 1–19. https://doi.org/10.1128/AAC.00008-18
      24. Huerga, H., Van Cutsem, G., Ben Farhat, J., Puren, A., Bouhenia, M., Wiesner, L., Dlamini, L., Maman, D., Ellman, T., & Etard, J. F. (2018). Progress towards the UNAIDS 90-90-90 goals by age and gender in a rural area of KwaZulu-Natal, South Africa: A household-based community cross-sectional survey. BMC Public Health, 18(1), 303. https://doi.org/10.1186/s12889-018-5208-0
      25. Innes, S., van der Laan, L., Anderson, P. L., Cotton, M., & Denti, P. (2018). Can We Improve Stavudine’s Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing. Antimicrobial Agents and Chemotherapy, 62(11), 1–10. https://doi.org/10.1128/AAC.00761-18
      26. Johnston, J., Orrell, C., Smith, P., Joubert, A., & Wiesner, L. (2018). A validated liquid chromatography/tandem mass spectrometry method for the analysis of efavirenz in 0.2 mg hair samples from human immunodeficiency virus infected patients. Rapid Communications in Mass Spectrometry, 32(8), 657–664. https://doi.org/10.1002/rcm.8077
      27. Kloprogge, F., Workman, L., Borrmann, S., Tékété, M., Lefèvre, G., Hamed, K., Piola, P., Ursing, J., Kofoed, P. E., Mårtensson, A., Ngasala, B., Björkman, A., Ashton, M., Friberg Hietala, S., Aweeka, F., Parikh, S., Mwai, L., Davis, T. M. E., Karunajeewa, H., Salman, S., Checchi, F., Fogg, C., Newton, P. N., Mayxay, M., Deloron, P., Faucher, J. F., Nosten, F., Ashley, E. A., McGready, R., van Vugt, M., Proux, S., Price, R. N., Karbwang, J., Ezzet, F., Bakshi, R., Stepniewska, K., White, N. J., Guerin, P. J., Barnes, K. I., & Tarning, J. (2018). Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Medicine, 15(6), e1002579. https://doi.org/10.1371/journal.pmed.1002579
      28. Kredo, T., Wiseman, R., Gray, A., Parrish, A., Miot, J., Cohen, K., Jamaloodien, K., & Blockman, M. (2018). How good are our guidelines? Four years of experience with the SAMJ’s AGREE II review of submitted clinical practice guidelines. South African Medical Journal, 108(11), 883–885. https://doi.org/10.7196/SAMJ.2018.v108i11.13646
      29. Kwara, A., Yang, H., Antwi, S., Enimil, A., Gillani, F. S., Dompreh, A., Ortsin, A., Opoku, T., Bosomtwe, D., Sarfo, A., Wiesner, L., Norman, J., Alghamdi, W. A., Langaee, T., Peloquin, C. A., Court, M. H., & Greenblatt, D. J. (2018). Effect of rifampin/isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children aged 3 to 14 years old. Antimicrobial Agents and Chemotherapy, 63(1), 1–12. https://doi.org/10.1128/AAC.01657-18
      30. L’abbate, F. P., Müller, R., Openshaw, R., Combrinck, J. M., de Villiers, K. A., Hunter, R., & Egan, T. J. (2018). Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites. European Journal of Medicinal Chemistry, 159, 243–254. https://doi.org/10.1016/j.ejmech.2018.09.060
      31. Maartens, G., Brill, M. J. E., Pandie, M., & Svensson, E. M. (2018). Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis. The International Journal of Tuberculosis and Lung Disease, 22(1), 26–29. https://doi.org/10.5588/ijtld.17.0615
      32. Maartens, G., Stewart, A., Griesel, R., Kengne, A. P., Dube, F., Nicol, M., Rangaka, M. X., & Mendelson, M. (2018). Development of a clinical prediction rule to diagnose Pneumocystis jirovecii pneumonia in the World Health Organization’s algorithm for seriously ill HIV-infected patients. Southern African Journal of HIV Medicine, 19(1), 1–6. https://doi.org/10.4102/sajhivmed.v19i1.851
      33. Magombedze, G., Pasipanodya, J. G., Srivastava, S., Deshpande, D., Visser, M. E., Chigutsa, E., McIlleron, H., & Gumbo, T. (2018). Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges. Clinical Infectious Diseases, 67(suppl_3), S349–S358. https://doi.org/10.1093/cid/ciy623
      34. Meintjes, G., Stek, C., Blumenthal, L., Thienemann, F., Schutz, C., Buyze, J., Ravinetto, R., van Loen, H., Nair, A., Jackson, A., Colebunders, R., Maartens, G., Wilkinson, R. J., & Lynen, L. (2018). Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. New England Journal of Medicine, 379(20), 1915–1925. https://doi.org/10.1056/NEJMoa1800762
      35. Mendelson, F., Griesel, R., Tiffin, N., Rangaka, M., Boulle, A., Mendelson, M., & Maartens, G. (2018). C-reactive protein and procalcitonin to discriminate between tuberculosis, Pneumocystis jirovecii pneumonia, and bacterial pneumonia in HIV-infected inpatients meeting WHO criteria for seriously ill: A prospective cohort study. BMC Infectious Diseases, 18(1), 399. https://doi.org/10.1186/s12879-018-3303-6
      36. Myers, B., Bouton, T. C., Ragan, E. J., White, L. F., McIlleron, H., Theron, D., Parry, C. D. H., Horsburgh, C. R., Warren, R. M., & Jacobson, K. R. (2018). Impact of alcohol consumption on tuberculosis treatment outcomes: A prospective longitudinal cohort study protocol. BMC Infectious Diseases, 18(1), 488. https://doi.org/10.1186/s12879-018-3396-y
      37. Naidoo, A., Ramsuran, V., Chirehwa, M., Denti, P., McIlleron, H., Naidoo, K., Yende-Zuma, N., Singh, R., Ngcapu, S., Chaudhry, M., Pepper, M. S., & Padayatchi, N. (2018). Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics, 19(1), 17–29. https://doi.org/10.2217/pgs-2017-0144
      38. Nyangahu, D. D., Lennard, K. S., Brown, B. P., Darby, M. G., Wendoh, J. M., Havyarimana, E., Smith, P., Butcher, J., Stintzi, A., Mulder, N., Horsnell, W., & Jaspan, H. B. (2018). Disruption of maternal gut microbiota during gestation alters offspring microbiota and immunity. Microbiome, 6(1), 124. https://doi.org/10.1186/s40168-018-0511-7
      39. Pasipanodya, J. G., Smythe, W., Merle, C. S., Olliaro, P. L., Deshpande, D., Magombedze, G., McIlleron, H., & Gumbo, T. (2018). AI-derived three-way concentration-dependent antagonism of gatifloxacin, pyrazinamide, and rifampicin during treatment of pulmonary tuberculosis. Clinical Infectious Diseases, 67(suppl_3), S284–S292. https://doi.org/10.1093/cid/ciy610
      40. Pillai, G., Chibale, K., Constable, E. C., Keller, A. N., Gutierrez, M. M., Mirza, F., Sengstag, C., Masimirembwa, C., Denti, P., Maartens, G., Ramsay, M., Ogutu, B., Makonnen, E., Gordon, R., Ferreira, C. G., Goldbaum, F. A., Degrave, W. M. S., Spector, J., Tadmor, B., & Kaiser, H. J. (2018). The Next Generation Scientist program: Capacity-building for future scientific leaders in low- and middle-income countries. BMC Medical Education, 18(1), 233. https://doi.org/10.1186/s12909-018-1331-y
      41. Ross, I. L., Jones, J., & Blockman, M. (2018). We are tired of “adrenal fatigue.” South African Medical Journal, 108(9), 724. https://doi.org/10.7196/SAMJ.2018.v108i9.13292
      42. Sadiq, H., Barnes, K. I., Price, M., Gumedze, F., & Morrell, R. G. (2018). Academic promotions at a South African university: questions of bias, politics and transformation. Higher Education. https://doi.org/10.1007/s10734-018-0350-2
      43. Schalkwijk, S., ter Heine, R., Colbers, A. C., Huitema, A. D. R., Denti, P., Dooley, K. E., Capparelli, E., Best, B. M., Cressey, T. R., Greupink, R., Russel, F. G. M., Mirochnick, M., & Burger, D. M. (2018). A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clinical Pharmacokinetics, 57(11), 1421–1433. https://doi.org/10.1007/s40262-018-0642-9
      44. Schnippel, K., Ndjeka, N., Maartens, G., Meintjes, G., Master, I., Ismail, N., Hughes, J., Ferreira, H., Padanilam, X., Romero, R., te Riele, J., & Conradie, F. (2018). Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. The Lancet Respiratory Medicine, 6(9), 699–706. https://doi.org/10.1016/S2213-2600(18)30235-2
      45. Sekaggya-Wiltshire, C., Von Braun, A., Lamorde, M., Ledergerber, B., Buzibye, A., Henning, L., Musaazi, J., Gutteck, U., Denti, P., De Kock, M., Jetter, A., Byakika-Kibwika, P., Eberhard, N., Matovu, J., Joloba, M., Muller, D., Manabe, Y. C., Kamya, M. R., Corti, N., Kambugu, A., Castelnuovo, B., & Fehr, J. S. (2018). Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients with Low Isoniazid and Rifampicin Concentrations. Clinical Infectious Diseases, 67(5), 708–716. https://doi.org/10.1093/cid/ciy179
      46. Stott, K. E., Pertinez, H., Sturkenboom, M. G. G., Boeree, M. J., Aarnoutse, R., Ramachandran, G., Requena-Méndez, A., Peloquin, C., Koegelenberg, C. F. N., Alffenaar, J. W. C., Ruslami, R., Tostmann, A., Swaminathan, S., McIlleron, H., & Davies, G. (2018). Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: A systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 73(9), 2305–2313. https://doi.org/10.1093/jac/dky152
      47. Svensson, E. M., du Bois, J., Kitshoff, R., de Jager, V. R., Wiesner, L., Norman, J., Nachman, S., Smith, B., Diacon, A. H., Hesseling, A. C., & Garcia-Prats, A. J. (2018). Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. British Journal of Clinical Pharmacology, 84(10), 2384–2392. https://doi.org/10.1111/bcp.13696
      48. Svensson, E. M., Yngman, G., Denti, P., McIlleron, H., Kjellsson, M. C., & Karlsson, M. O. (2018). Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy. Clinical Pharmacokinetics, 57(5), 591–599. https://doi.org/10.1007/s40262-017-0577-6
      49. Swanepoel, C. R., Atta, M. G., D’Agati, V. D., Estrella, M. M., Fogo, A. B., Naicker, S., Post, F. A., Wearne, N., Winkler, C. A., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., Wyatt, C. M., Abu-Alfa, A., Adu, D., Agodoa, L. Y., Alpers, C. E., Arogundade, F. A., Ashuntantang, G., Bagnis, C. I., Bhimma, R., Brocheriou, I., Cohen, A. H., Cohen, K., Cook, H. T., de Seigneux, S., Fabian, J., Finkelstein, F. O., Haas, M., Hamzah, L., Hendry, B. M., Imonje, V., Jennette, J. C., Kimmel, P. L., Klotman, M. E., Klotman, P. E., Larsen, C. P., McCulloch, M. I., Mosiane, P., Nast, C. C., Okpechi, I. G., Ray, P. E., Rosenberg, A. Z., Ross, M. J., Ryom, L., Truong, L., Ulasi, I., Vogt, L., & Zeier, M. (2018). Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 93(3), 753–760. https://doi.org/10.1016/j.kint.2017.11.007
      50. Taylor, W. R., Naw, H. K., Maitland, K., Williams, T. N., Kapulu, M., D’Alessandro, U., Berkley, J. A., Bejon, P., Okebe, J., Achan, J., Amambua, A. N., Affara, M., Nwakanma, D., van Geertruyden, J. P., Mavoko, M., Lutumba, P., Matangila, J., Brasseur, P., Piola, P., Randremanana, R., Lasry, E., Fanello, C., Onyamboko, M., Schramm, B., Yah, Z., Jones, J., Fairhurst, R. M., Diakite, M., Malenga, G., Molyneux, M., Rwagacondo, C., Obonyo, C., Gadisa, E., Aseffa, A., Loolpapit, M., Henry, M. C., Dorsey, G., John, C., Sirima, S. B., Barnes, K. I., Kremsner, P., Day, N. P., White, N. J., & Mukaka, M. (2018). Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. BMC Medicine, 16(1), 11. https://doi.org/10.1186/s12916-017-0990-6
      51. Thuboy, B., Kellermann, T., Castel, S., Norman, J., Joubert, A., Garcia-Prats, A. J., Hesseling, A. C., & Wiesner, L. (2018). The determination of capreomycin in human plasma by LC–MS/MS using ion-pairing chromatography and solid-phase extraction. Biomedical Chromatography, 32(9), e4269. https://doi.org/10.1002/bmc.4269
      52. Wilson, D., Moosa, M.-Y. S., Cohen, T., Cudahy, P., Aldous, C., & Maartens, G. (2018). Evaluation of tuberculosis treatment response with serial C-reactive protein measurements. Open Forum Infectious Diseases, 5(11), ofy253. https://doi.org/10.1093/ofid/ofy253
      53. Woodland, J. G., Hunter, R., Smith, P. J., & Egan, T. J. (2018). Chemical Proteomics and Super-resolution Imaging Reveal That Chloroquine Interacts with Plasmodium falciparum Multidrug Resistance-Associated Protein and Lipids. ACS Chemical Biology, 13(10), 2939–2948. https://doi.org/10.1021/acschembio.8b00583

    • 2017

      1. Antwi S, Yang H, Enimil A, Sarfo AM, Gillani FS, Ansong D, Dompreh A, Orstin A, Opoku T, Bosomtwe D, Wiesner L, Norman J, Peloquin CA, Kwara A. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection. Antimicrobial agents and chemotherapy. 2017; 61(2):e01701-16.
      2. Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P. Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. J Antimicrob Chemother. 2017 Jan;72(1):190-199.
      3. Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H. Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets. AIDS. 2017 Apr 24;31(7):905-915.
      4. Blockman M. Warfarin: better the devil you know. Cardiovascular Journal of Africa 2017;28:344-345.
      5. Bouazza N, Cressey TR, Foissac F, Bienczak A, Denti P, McIlleron H, Burger D, Penazzato M, Lallemant M, Capparelli EV, Treluyer JM, Urien S. Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients. J Antimicrob Chemother. 2017 Feb;72(2):490-495.
      6. Bowles S, Joubert E, de Beer D, Louw J, Brunschwig C, Njoroge M, Lawrence N,Wiesner L, Chibale K, Muller C. Intestinal Transport Characteristics and Metabolism of C-Glucosyl Dihydrochalcone, Aspalathin. Molecules (Basel, Switzerland). 2017; 22(4).
      7. Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, Richards GA, van Zyl Smit R, Smith C, Wasserman S, Whitelaw AC, Feldman C. South African guideline for the management of community-acquired pneumonia in adults. Journal of Thoracic Disease 2017;9(6):1469-1502.
      8. Brill MJ, Svensson EM, Pandie M, Maartens G, Karlsson MO. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis. International Journal of Antimicrobial Agents 2017;49(2):212-7.
      9. Chirehwa MT, McIlleron H, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, Denti P. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. Antimicrob Agents Chemother. 2017;61(8):e00490-17.
      10. Cudahy PG, Wilson D, Allwood BW, Maartens G, Dawson R. Diagnostic outcomes after chest radiograph interpretation in patients with suspected tuberculosis and negative sputum smears in a high burden HIV and tuberculosis setting. Open Forum Infectious Diseases 2017;4(3):ofx123
      11. Decloedt E, Lesosky M, Maartens G, Joska J. Renal safety of lithium in HIV‑infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo‑controlled trial. AIDS Research and Therapy 2017;14:6.
      12. de Kock M, Tarning J, Workman L, Nyunt MM, Adam I, Barnes KI, Denti P. Pharmacokinetics of sulfadoxine and pyrimethamine for intermittent preventive treatment of malaria during pregnancy and after delivery. CPT: Pharmacometrics & Systems Pharmacology 2017;6:430-438.
      13. De Waal R, Cohen K, Fox MP, Stinson K, Maartens G, Boulle A, Igumbor EU, Davies MA. Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study. Journal of the International AIDS Society 2017;20:1-8.
      14. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron
      15. H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):291-360.
      16. Dhingra SK, Redhi D, Combrinck JM, Yeo T, Okombo J, Henrich PP, Cowell AN, Gupta P, Stegman ML, Hoke JM, Cooper RA.. A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine. mBio 2017, 8(3), pii: e00303-17.
      17. Ebrahim I, Blockman M. Metabolic acidosis in a patient with metformin overdose. S Afr Med J 2017;107(2):110-111.
      18. Engel ME, Cohen K, Gounden R, Barth DD, Kengne AP, Whitelaw AC, Francis V, Badri M, Stewart A, Dale JB, Mayosi BM, Maartens G. The Cape Town clinical decision rule for streptococcal pharyngitis in children. Pediatric Infectious Diseases Journal 2017;36(3):250-5
      19. Espinoza-Moraga M, Singh K, Njoroge M, Kaur G, Okombo J, De Kock C, Smith PJ, Wittlin S, Chibale K. Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents. Bioorganic & Medicinal Chemistry Letters 27 (2017) 658–661
      20. Fortuin-de Smidt M, de Waal R, Cohen K, Technau K, Stinson K, Maartens G, Boulle A, Igumbor EU, Davies MA. First-line antiretroviral drug discontinuations in children. PLoS ONE 2017;12:e0169762
      21. Gutierrez MM, Pillai G, Felix S, Romero F, Onyango KO, Owusu-Agyei S, Asante KP, Barnes KI, Sinxadi P, Allen E, Abdulla S, Masimirembwa C, Munyoro M, Yimer G, Gebre-Mariam T, Spector J, Ogutu B. Building Capability for Clinical Pharmacology Research in Sub-Saharan Africa. Clin Pharmacol Ther. 2017 Nov;102(5):786-795.
      22. Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, Ouedraogo JB, Borrmann S, Mwai L, Nsanzabana C, Price RN, Dahal P, Sambol NC, Parikh S, Nosten F, Ashley EA, Phyo AP, Lwin KM, McGready R, Day NP, Guerin PJ, White NJ, Barnes KI, Tarning J. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Med. 2017 Jan 10;14(1):e1002212
      23. Huerga H, Shiferie F, Grebe E, Giuliani R, Ben Farhat J, Van Cutsem G, Cohen K. A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa. BMC Infect Dis 2017;7:653.
      24. Janssen S, Schutz C, Ward AM, Nemes E, Wilkinson KA, Scrievn J, Huson MA, Aben N, Maartens G, Burton R, Wilkinson RJ, Grobusch MP, van der Poll T, Meintjes G. Mortality in severe HIV-TB associates with innate immune activation and dysfunction of monocytes. Clinical Infectious Diseases 2017;65:73-82.
      25. Janssen S, Schutz C, Ward AM, Huson MA, Wilkinson RJ, Burton R, Maartens G, Wilkinson KA, Meijers JC, Lutter R, Grobusch MP, Meintjes G, van der Poll T. Hemostatic changes associate with mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. Journal of Infectious Diseases 2017;215:247-58.
      26. Jones ESW, Lesosky M, Blockman M, Castel S, Decloedt EH, Schwager SLU, Sturrock ED, Wiesner L, Rayner BL. Therapeutic drug monitoring of amlodipine and the Z-FHL/HHL ratio: Adherence tools in patients referred for apparent treatment-resistant hypertension. South African Medical Journal 2017; 107(10):887-891.
      27. Joshi MC, Okombo J, Nsumiwa S, Ndove J, Taylor D, Wiesner L, Hunter R, Chibale K, Egan TJ. 4‑Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice. J Med Chem 2017;60:10245−56.
      28. Maartens G, Boffito M, Flexner C. Compatibility of next generation first line antiretrovirals with rifampicin-based anti-tuberculosis therapy in resource limited settings. Current Opinion in HIV and AIDS 2017;12:355-8
      29. Maartens G, Meintjes G. Resistance matters in EARNEST. [Invited comment]. Lancet HIV 2017;4:e323-4
      30. Mandimika N, Barnes KI, Chandler CI, Pace C, Allen EN. Working towards consensus on methods used to elicit participant-reported safety data in uncomplicated malaria clinical drug studies: a Delphi technique study. Malar J. 2017 Jan 28;16(1):52.
      31. Marais BJ, Heemskerk AD, Marais SS, van Crevel R, Rohlwink U, Caws M, Meintjes G, Misra UK, Mai NTH, Ruslami R, Seddon JA, Solomons R, van Toorn R, Figaji A, McIlleron H, Aarnoutse R, Schoeman JF, Wilkinson RJ, Thwaites GE; Tuberculous Meningitis International Research Consortium. Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies. Clin Infect Dis.
      32. 2017 Feb 15;64(4):501-509.
      33. McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, Msandiwa R, Wiesner L, Velaphi S, Lala SG, Chaisson RE, Martinson N, Dooley KE; Tshepiso Study Team. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. J Antimicrob Chemother. 2017 Jul 1;72(7):2028-2034.
      34. Monera-Penduka TG, Maponga CC, Wolfe AR, Wiesner L, Morse GD, Nhachi CF. Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. AIDS Research and Therapy. 2017; 14:12.
      35. Mouton JP, Mehta U, Rossiter DP, Maartens G, Cohen K. Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system. PLoS ONE 2017;12(2): e0172830.
      36. Mouton JP, Cohen K, Maartens G. Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. Expert Review of Clinical Pharmacology 2016;9:901-15.
      37. Naidoo A, Naidoo K, McIlleron H, Essack S, Padayatchi N. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis. J Clin Pharmacol. 2017 Nov;57(11):1369-1386.
      38. Naidoo A, Chirehwa M, McIlleron H, Naidoo K, Essack S, Yende-Zuma N, Kimba-Phongi E, Adamson J, Govender K, Padayatchi N, Denti P. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. J Antimicrob Chemother. 2017;72(5):1441-1449.
      39. Olliaro PL, Merle C, Mthiyane T, Bah B, Kassa F, Amukoye E, N Diaye A, Perronne C, Lienhardt C, McIlleron H, Fielding K. Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e01834-16.
      40. Orrell C, Cohen K, Leisegang R, Bangsberg DR, Wood R, Maartens G. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes? AIDS Research and Therapy 2017;14:20
      41. Papavarnavas NS, Manning K, Conrad F, Govender M, Maartens G. Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study. AIDS Research and Therapy 2017;14:23
      42. Rockwood N, Pasipanodya JG, Denti P, Sirgel F, Lesosky M, Gumbo T, Meintjes G, McIlleron H, Wilkinson RJ. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. Clin Infect Dis. 2017 May 15;64(10):1350-1359.
      43. Singh K, Okombo J, Brunschwig C, Ndubi F, Barnard L, Wilkinson C, Njogu PM, Njoroge M, Laing L, Machado M, Prudêncio M, Reader J, Botha M, Nondaba S, Birkholtz LM, Lauterbach S, Churchyard A, Coetzer TL, Burrows JN, Yeates C, Denti P, Wiesner L, Egan TJ, Wittlin S, Chibale K. Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model. J. Med. Chem. 2017;60:1432−48.
      44. Singh K, Okombo J, Brunschwig C, Ndubi F, Barnard L, Wilkinson C, Njogu PM, Njoroge M, Laing L, Machado M. Antimalarial Pyrido [1, 2-a] benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model. Journal of Medicinal Chemistry 2017;60:1432-1448.
      45. Sumner T, Houben RM, Rangaka MX, Maartens G, Boulle A, Wilkinson RJ, White RG. Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. AIDS 2016;30:1279-86.
      46. Variava E, Sigauke FR, Norman J, Rakgokong M, Muchichwa P, Mochan A, Maartens G, Martinson NA. Late efavirenz-induced ataxia and encephalopathy: a case series. Journal of Acquired Immune Deficiency Syndromes 2017;75:577-9.
      47. Vanaerschot M, Lucantoni L, Li T, Combrinck JM, Ruecker A, Kumar TS, Rubiano K, Ferreira PE, Siciliano G, Gulati S, Henrich PP. Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity. Nature Microbiology 2017;2(10):1403-14.
      48. Wicht KJ, Combrinck JM, Smith PJ, Hunter R, Egan TJ. Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against Plasmodium falciparum. ACS Medicinal Chemistry Letters 2017;8:201-205.

    • 2016

      1. Abrahams Z, Lesosky M, Levitt N, Maartens G, Dave J [joint senior authorship]. Changes in body fat distribution on dual-energy x-ray absorptiometry in black South Africans starting first-line antiretroviral therapy. AIDS Patient Care and STDs 2016;30(10):455-62.
      2. Adams M, Barnard L, de Kock C, Smith PJ, Wiesner L, Chibale K, Smith GS. Cyclopalladated organosilane-tethered thiosemicarbazones: novel strategies for improving antiplasmodial activity. Dalton Trans. 2016 Apr 7;45(13):5514-20.
      3. Adams M, Stringer T, de Kock C, Smith PJ, Land KM, Liu N, Tam C, Cheng LW, Njoroge M, Chibale K, Smith GS. Bioisosteric ferrocenyl-containing quinolines with antiplasmodial and antitrichomonal properties. Dalton Trans. 2016 Nov 29;45 (47):19086-19095.
      4. Baartzes N, Stringer T, Chellan P, Combrinck JM, Smith PJ, Hutton AT, Smith GS. Synthesis, characterization, antiplasmodial evaluation and electrochemical studies of water-soluble heterobimetallic ferrocenyl complexes. Inorganica Chimica Acta 2016;446:111-115.
      5. Bana TM, Lesosky M, Pepper DJ, van der Plas H, Schutz C, Goliath R, Morroni C, Mendelson M, Maartens G, Wilkinson RJ, Meintjes G. Prolonged tuberculosis-associated immune reconstitution inflammatory syndrome: characteristics and risk factors. BMC Infectious Diseases 2016;16(1):518.
      6. Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesseling AC. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9.
      7. Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H. 2016. Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children. J Acquir Immune Defic Syndr 2016;73(2):161-8.
      8. Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C, Kekitiinwa A, Owen A, Walker AS, Gibb DM, McIlleron H, Burger D, Denti P. The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. Br J Clin Pharmacol. 2016 Jul;82(1):185-98.
      9. Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P. Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. J Antimicrob Chemother. 2017;72(1):190-199.
      10. Bouazza N, Cressey TR, Foissac F, Bienczak A, Denti P, McIlleron H, Burger D, Penazzato M, Lallemant M, Capparelli E V., Treluyer J-M, Urien S. 2017. Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients. J Antimicrob Chemother 72:490–495.
      11. Buzzatti N, De Bonis M, Denti P, Barili F, Schiavi D, Di Giannuario G, La Canna G, Alfieri O. What is a "good" result after transcatheter mitral repair? Impact of 2+ residual mitral regurgitation. J Thorac Cardiovasc Surg. 2016 Jan;151(1):88-96
      12. Chirehwa MT, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, McIlleron H, Denti P. Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3262.
      13. Chughlay MF, Kramer N, Spearman CW, Werfalli M, Engel ME, Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review. Br J Clin Pharmacol. 2016;81(6):1021-9
      14. Court R, Gordon M, Cohen K, Stewart A, Gosnell B, Wiesner L, Maartens G. Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. International Journal of Antimicrobial Agents 2016;48(2):158-62.
      15. Dave JA, Levitt NS, Ross IL, Lacerda M, Maartens G, Blom D. Antiretroviral therapy increases the prevalence of dyslipidemia in South African HIV-infected patients. PLoS ONE 2016;11(3):e0151911.
      16. Decloedt E, Freeman C, Howels F, Casson-Cook M, Lesosky M, Koutsilieri E, Lovestone S, Maartens G, Joska J. Moderate to severe HIV associated neurocognitive impairment: a randomized placebo controlled trial of lithium. Medicine (Baltimore) 2016 Nov;95(46):e5401.
      17. Denoeud-Ndam L, Dicko A, Baudin E, Guindo O, Grandesso F, Diawara H, Sissoko S, Sanogo K, Traoré S, Keita S, Barry A, de Smet M, Lasry E, Smit M, Wiesner L, Barnes KI, Djimde AA, Guerin PJ, Grais RF, Doumbo OK, Etard JF. Efficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger. BMC Med. 2016 Oct 24;14(1):167.
      18. Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H, Dooley KE, Tshepiso Study Team. 2016. Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South Africa. Antimicrob Agents Chemother. 60:1234–41.
      19. De Waal R, Cohen K, Fox MP, Stinson K, Maartens G, Boulle A, Davies MA. Clinician compliance with laboratory monitoring and prescribing guidelines in HIV1-infected patients receiving tenofovir. South African Medical Journal 2016;106:369-71.
      20. Dheda K, Esmail A, Limberis J, Maartens G. Selected questions and controversies about bedaquiline: a view from the field. Int J Tuberc Lung Dis 20(12):S24–S32
      21. Dheda K, Barry CE, Maartens G. Tuberculosis. Lancet 2016;387:1211-26.
      22. Ekengard E, Kumar K, Fogeron T, de Kock C, Smith PJ, Haukka M, Monari M, Nordlander E. Pentamethylcyclopentadienyl-rhodium and iridium complexes containing (N^N and N^O) bound chloroquine analogue ligands: synthesis, characterization and antimalarial properties. Dalton Trans. 2016 Mar 7;45(9):3905-17.
      23. Espinoza-Moraga M, Singh K, Njoroge M, Kaur G, Okombo J, De Kock C, Smith PJ, Wittlin S, Chibale K. Synthesis and biological characterisation of ester and amide derivatives of fusidic acid as antiplasmodial agents. Bioorganic & Medicinal Chemistry Letters 2017;27:658–661
      24. Gabryszewski SJ, Dhingra SK, Combrinck JM, Lewis IA, Callaghan PS, Hassett MR, Siriwardana A, Henrich PP, Lee AH, Gnadig NF, Musset L5, Llinas M, Egan TJ, Roepe PD, Fidock DA. Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology. PLoS Pathog 2016;12(11): e1005976.
      25. Gibhard L, Pravin K, Abay E, Wilhelm A, Swart K, Lawrence N, Khoury R, van der Westhuizen J, Smith P, Wiesner L. In Vitro and In Vivo Pharmacokinetics of Aminoalkylated Diarylpropanes NP085 and NP102. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3065-9.
      26. Hennig S, Svensson EM, Niebecker R, Fourie PB, Weiner MH, Bonora S, Peloquin CA, Gallicano K, Flexner C, Pym A, Vis P, Olliaro PL, McIlleron H, Karlsson MO. Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. J Antimicrob Chemother. 2016 May;71(5):1330-40.
      27. Hoffmann CJ, Cohn S, Mashabela F, Hoffmann JD, McIlleron H, Denti P, Haas DW, Dooley KE, Martinson NA, Chaisson RE. Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):31-7.
      28. Huerga H, Van Cutsem G, Ben Farhat J, Reid M, Bouhenia M, Maman D, Wiesner L, Etard JF, Ellman T. Who Needs to Be Targeted for HIV Testing and Treatment in KwaZulu-Natal? Results from a Population-Based Survey. J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):411-418. PubMed PMID: 27243903; PubMed Central PMCID: PMC5172512.
      29. Karamchand S, Leisegang R, Schomaker M, Maartens G, Hislop M, Dave JA, Levitt NS, Walters L, Cohen K. Risk factors for incident diabetes in a cohort taking first line non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Medicine (Baltimore) 2016;95:e2844.
      30. Kim AA, Mukui I, Young PW, Mirjahangir J, Mwanyumba S, Wamicwe J, Bowen N, Wiesner L, Ng'ang'a L, De Cock KM; KAIS Study Group. Undisclosed HIV infection and antiretroviral therapy use in the Kenya AIDS indicator survey 2012: relevance to national targets for HIV diagnosis and treatment. AIDS. 2016 Nov 13;30(17):2685-2695.
      31. Kim AA, Mukui I, Young PW, Mirjahangir J, Mwanyumba S, Wamicwe J, Bowen N, Wiesner L, Ng'ang'a L, De Cock KM; KAIS Study Group. Undisclosed HIV infection and ART use in the Kenya AIDS indicator survey 2012: relevance to targets for HIV diagnosis and treatment in Kenya. AIDS. 2016 Nov 13;30(17):2685-2695.
      32. Kredo T, Mauff K, Workman L, Van der Walt JS, Wiesner L, Smith PJ, Maartens G, Cohen K, Barnes KI. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients. BMC Infectious Diseases 2016;16:30.
      33. Kwara A, Enimil A, Gillani FS, Yang H, Sarfo AM, Dompreh A, Ortsin A, Osei-Tutu L, Kwarteng Owusu S, Wiesner L, Norman J, Kurpewski J, Peloquin CA, Ansong D, Antwi S. Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection. J Pediatric Infect Dis Soc. 2016 Dec;5(4):356-365.
      34. La Canna G, Denti P, Buzzatti N, Alfieri O. Recent developments in percutaneous mitral valve treatment. Expert Rev Cardiovasc Ther. 2016 Feb;14(2):217-28.
      35. Le Manach C, Nchinda AT, Paquet T, Gonzàlez Cabrera D, Younis Y, Han Z, Bashyam S, Zabiulla M, Taylor D, Lawrence N, White KL, Charman SA, Waterson D, Witty MJ, Wittlin S, Botha ME, Nondaba SH, Reader J, Birkholtz LM, Jiménez-Díaz MB, Martínez MS, Ferrer S, Angulo-Barturen I, Meister S, Antonova-Koch Y, Winzeler EA, Street LJ, Chibale K. Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle. J Med Chem. 2016 Nov 10;59(21):9890-9905.
      36. Levitt NS, Peer N, Steyn K, Lombard C, Maartens G, Lambert EV, Dave JA. Increased risk of dysglycaemia in South Africans with HIV; especially those on protease inhibitors. Diabetes Research and Clinical Practice 119 (2016) 41-47
      37. Maartens G, Benson CA. Linezolid for Treating Tuberculosis: A Delicate Balancing Act. EBioMedicine. 2015 Oct 21;2(11):1568-9.
      38. Maneli MH, Wiesner L, Tinguely C, Davids LM, Spengane Z, Smith P, van Wyk JC, Jardine A, Khumalo NP. Combinations of potent topical steroids, mercury and hydroquinone are common in internationally manufactured skin-lightening products: a spectroscopic study. Clin Exp Dermatol. 2016 Mar;41(2):196-201.
      39. McIlleron H, Hundt H, Smythe W, Bekker A, Winckler J, van der Laan L, Smith P, Zar HJ, Hesseling AC, Maartens G, Wiesner L, van Rie A. Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes. Int J Tuberc Lung Dis. 2016 Jul;20(7):915-9.
      40. Moholisa RR, Schomaker M, Kuhn L, Castel S, Wiesner L, Coovadia A, Strehlau R, Patel F, Pinillos F, Abrams EJ, Maartens G, McIlleron H. Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. Pediatr Infect Dis J. 2016 Dec;35(12):e378-e383.
      41. Mouton JP, Njuguna CW, Kramer N, Stewart A, Mehta U, Blockman M, Fortuin-De Smidt M, De Waal R, Parrish AG, Wilson DPK, Igumbor EU, Aynalem G, Dheda M, Maartens G, Cohen K. Adverse drug reactions causing admission to medical wards: A cross-sectional survey at 4 hospitals in South Africa. Medicine (Baltimore) 2016; 95:e3437
      42. Mpeta B, Kampira E, Castel S, Mpye KL, Soko ND, Wiesner L, Smith P, Skelton M, Lacerda M, Dandara C. Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans. Pharmacogenomics. 2016 May;17(7):679-90.
      43. Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Lancet Infect Dis. 2016 Feb;16(2):169-79.
      44. Ngwane AH, Panayides JL, Chouteau F, Macingwana L, Viljoen A, Baker B, Madikane E, de Kock C, Wiesner L, Chibale K, Parkinson CJ, Mmutlane EM, van Helden P, Wiid I. Design, synthesis, and In vitro antituberculosis activity of 2(5H)-Furanone derivatives. IUBMB Life. 2016 Aug;68(8):612-20.
      45. Njuguna C, Stewart A, Mouton JP, Blockman M, Maartens G, Swart A, Chisholm B, Jones J, Dheda M, Igumbor EU, Cohen K. Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports. Drug Safety 2016 Feb;39(2):159-69.
      46. Njuguna C, Swart A, Blockman M, Maartens G, Chisholm B, Stewart A, Uys A, Cohen K. Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. AIDS Research and Therapy 2016 Nov 16;13:40.
      47. Orrell C, Bienczak A, Cohen K, Bangsberg D, Wood R, Maartens G, Denti P. Effect of mid-dose efavirenz concentrations and CYP2B6 genotyping on viral suppression in patients on first-line ART. International Journal of Antimicrobial Agents 2016 Jun;47(6):466-72.
      48. Pandie M, Wiesner L, McIlleron H, Hughes J, Conradie F, Variava E, Maartens G. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir-ritonavir and nevirapine in HIV-infected patients with drug resistant tuberculosis. Journal of Antimicrobial Chemotherapy 2016;71:1037-40.
      49. Rockwood N, Meintjes G, Chirehwa M, Wiesner L, McIlleron H, Wilkinson RJ, Denti P. HIV-1 Coinfection Does Not Reduce Exposure to Rifampicin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6050-9.
      50. Sinxadi PZ, McIlleron HM, Dave JA, Smith PJ, Levitt NS, Haas DW, Maartens G. Plasma efavirenz concentrations are associated with plasma lipid and glucose concentrations. Medicine (Baltimore). 2016 Jan;95(2):e2385.
      51. Stewart A, Lehloenya R, Boulle A, de Waal R, Maartens G, Cohen K. Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis. Pharmacoepidemiology and Drug Safety 2016;25:1313-9.
      52. Stringer T, De Kock C, Guzgay H, Okombo J, Liu J, Kanetake S, Kim J, Tam C, Cheng LW, Smith PJ, Hendricks DT, Land KM, Egan TJ, Smith GS. Mono- and multimeric ferrocene congeners of quinoline-based polyamines as potential antiparasitics. Dalton Trans. 2016 Sep 14;45(34):13415-26.
      53. Sumner T, Houben RM, Rangaka MX, Maartens G, Boulle A, Wilkinson RJ, White RG. Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. AIDS 2016;30:1279-86.
      54. Swart M, Evans J, Skelton M, Castel S, Wiesner L, Smith PJ, Dandara C. An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. Front Genet. 2016 Jan 7;6:356.
      55. van Schalkwyk DA, Nash MN, Shafik SH, Summers RL, Lehane AM, Smith PJ, Martin RE. Verapamil-Sensitive Transport of Quinacrine and Methylene Blue via the Plasmodium falciparum Chloroquine Resistance Transporter Reduces the Parasite's Susceptibility to these Tricyclic Drugs. J Infect Dis. 2016 Mar 1;213(5):800-10.
      56. Wallis L, Malan M, Gouws C, Steyn D, Ellis S, Abay E, Wiesner L, Otto DP, Hamman J. Evaluation of Isolated Fractions of Aloe vera Gel Materials on Indinavir Pharmacokinetics: In vitro and in vivo Studies. Curr Drug Deliv. 2016;13(3):471-80.
      57. Wasserman S, Meintjes G, Maartens G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Review of Anti-infective Therapy 2016;14(10):901-15.
      58. Wicht KJ, Combrinck JM, Smith PJ, Hunter R, Egan TJ. Identification and SAR Evaluation of Hemozoin-Inhibiting Benzamides Active against Plasmodium falciparum. J Med Chem. 2016 Jul 14;59(13):6512-30.
      59. Zuma NH, Smit FJ, de Kock C, Combrinck J, Smith PJ, N'Da DD. Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin. Eur J Med Chem. 2016 Oct 21;122:635-46.

    • 2015

      1. Abay ET, van der Westuizen JH, Swart KJ, Gibhard L, Lawrence N, Dambuza N, Wilhelm A, Pravin K, Wiesner L. Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model. Malar J. 2015 Jan 6;14:8.
      2. Abdissa A, Olsen MF, Yilma D, Tesfaye M, Girma T, Christiansen M, Hagan CM, Wiesner L, Castel S, Aseffa A, McIlleron H, Petersen C, Friis H, Andersen AB. Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients. HIV Medicine 2015;16:403– 11.
      3. Abrahams Z, Dave JA, Maartens G, Levitt NS. Changes in blood pressure, glucose levels, insulin secretion and anthropometry after long term exposure to antiretroviral therapy in South African women. AIDS Res Ther 2015;12:24.
      4. Adams M, de Kock C, Smith PJ, Land KM, Liu N, Hopper M, Hsiao A, Burgoyne AR, Stringer T, Meyer M, Wiesner L, Chibale K, Smith GS. Improved antiparasitic activity by incorporation of organosilane entities into half-sandwich ruthenium(II) and rhodium(III) thiosemicarbazone complexes. Dalton Trans 2015;44(5):2456-68.
      5. Antel K, Singh N, Chisholm B, Heckmann JM: Encephalopathy after persistent vomiting: Three cases of non-alcohol-related Wernicke’s encephalopathy: S Afr Med J 2015;105(6):442-3.
      6. Brink AJ, Cotton M, Feldman C, Finlayson H, Friedman R, Green R, Hendson W, Hockman M, Maartens G, Madhi S, Reubenson G, Silverbauer E, Zietsman I. Updated recommendations for the management of upper respiratory tract infections in South Africa. S Afr Med J. 2015;105(5):344-52.
      7. Buzzatti N, Maisano F, Latib A, Taramasso M, Denti P, La Canna G, Colombo A, Alfieri O. Comparison of outcomes of percutaneous MitraClip versus surgical repair or replacement for degenerative mitral regurgitation in octogenarians. Am J Cardiol. 2015;115(4):487-92.
      8. Calitz C, Gouws C, Viljoen J, Steenekamp J, Wiesner L, Abay E, Hamman J. Herb-Drug Pharmacokinetic Interactions: Transport and Metabolism of Indinavir in the Presence of Selected Herbal Products. Molecules 2015;20(12):22113-27.
      9. Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 2015;59(1):38-45.
      10. Chirehwa MT, Rustomjee R, Mthiyane T, Onyebujoh P, Smith P, McIlleron H, Denti P. Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. Antimicrob Agents Chemother 2015;60(1):487-94.
      11. Chopra R, de Kock C, Smith P, Chibale K, Singh K. Ferrocene-pyrimidine conjugates: Synthesis, electrochemistry, physicochemical properties and antiplasmodial activities. Eur J Med Chem 2015;100:1-9.
      12. Chughlay MF, Njuguna C, Maartens G, Cohen K.: Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis. AIDS 2015;29:503-6.
      13.  Chughlay MF, Kramer N, Werfalli M, Spearman W, Engel ME, Cohen K. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocol. Syst Rev 2015;4:84.
      14. Combrinck JM, Fong KY, Gibhard L, Smith PJ, Wright DW, Egan TJ. Optimization of a multi-well colorimetric assay to determine haem species in Plasmodium falciparum in the presence of anti-malarials. Malar J 2015 Jun 24;14:253.
      15. Dambuza NS, Smith P, Evans A, Norman J, Taylor D, Andayi A, Egan T, Chibale K, Wiesner L. Antiplasmodial activity, in vivo pharmacokinetics and anti-malarial efficacy evaluation of hydroxypyridinone hybrids in a mouse model. Malar J 2015 Dec 16;14(1):505.
      16. Dambuza N, Smith P, Evans A, Taylor D, Chibale K, Wiesner L. A Pharmacokinetic Study of Antimalarial 3,5-Diaryl-2-aminopyridine Derivatives. Malar Res Treat. 2015;2015:405962.
      17. Dave JA, Cohen K, Micklesfield LK, Maartens G, Levitt NS. Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans. PLoS One 2015 Dec 3;10(12):e0144286.
      18. Dawson R, Narunsky K, Carman D, Gupte N, Whitelaw A, Efron A, Barnes GL, Hoffman J, Chaisson RE, McIlleron H, Dorman SE. Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis: Int J Tuberc Lung Dis 2015;19(7):780–6.
      19. Decloedt EH, Rosenkranz B, Maartens G, Joska J. Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations. Clin Pharmacokinetics 2015 Jun;54(6):581-98.
      20. Decloedt EH, van der Walt JS, McIlleron H, Wiesner L, Maartens G. The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals. Int J Tuberc Lung Dis 2015;19:1194-6.
      21. Denoeud-Ndam L, Dicko A, Baudin E, Guindo O, Grandesso F, Sagara I, Lasry E, Palma PP, Parra AM, Stepniewska K, Djimde AA, Barnes KI, Doumbo OK, Etard JF. A multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT study. BMC Infect Dis. 2015 Jun 12;15:228.
      22. Denti P, Jeremiah K, Chigutsa E, Faurholt-Jepsen D, PrayGod G, Range N, Castel S, Wiesner L, Hagen CM, Christiansen M, Changalucha J, McIlleron H, Friis H, Andersen AB. Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania. PLoS One 2015 Oct 26;10(10):e0141002.
      23. Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H, Dooley KE; Tshepiso Study Team. Population pharmacokinetics of rifampicin in pregnant women with tuberculosis and HIV co-infection in Soweto, South Africa. Antimicrob Agents Chemother. 2015;60:1234-41.
      24. Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Haas DW, Hull J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis 2015 Jan 15;211(2):197-205.
      25. du Plessis LH, Govender K, Denti P, Wiesner L. In vivo efficacy and bioavailability of lumefantrine: Evaluating the application of Pheroid technology. Eur J Pharm Biopharm 2015 Nov;97(Pt A):68-77.
      26. Gabriels G, Lambert M, Smith P, Wiesner L, Hiss D. Melamine contamination in nutritional supplements--Is it an alarm bell for the general consumer, athletes, and 'Weekend Warriors'? Nutr J. 2015 Jul 17;14:69.
      27. Garcia-Prats AJ, Draper HR, Thee S, Dooley KE, McIlleron HM, Seddon JA, Wiesner L, Castel S, Schaaf HS, Hesseling AC. Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. Antimicrob Agents Chemother 2015 Oct;59(10):6073-9.
      28. Gonzàlez Cabrera D, Douelle F, Le Manach C, Han Z, Paquet T, Taylor D, Njoroge M, Lawrence N, Wiesner L, Waterson D, Witty MJ, Wittlin S, Street LJ, Chibale K. Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines. J Med Chem 2015 Sep 24;58(18):7572-9.
      29. Govender K, Gibhard L, Du Plessis L, Wiesner L. Development and validation of a LC-MS/MS method for the quantitation of lumefantrine in mouse whole blood and plasma. J Chromatogr B Analyt Technol Biomed Life Sc. 2015 Mar 15;985:6-13.
      30. Gumbo T, Pasipanodya JG, Wash P, Burger A, McIlleron H. Reply to "breakpoints and drug exposure are inevitably closely linked". Antimicrob Agents Chemother. 2015 Feb;59(2):1385.
      31. Hennig S, Naiker S, Reddy T, Egan D, Kellerman T, Wiesner L, Owen A, McIlleron H, Pym A. Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. Antimicrob Agents Chemother 2015 Oct 19;60(1):617-20.
      32. Kaur H, Machado M, de Kock C, Smith P, Chibale K, Prudêncio M, Singh K. Primaquine-pyrimidine hybrids: synthesis and dual-stage antiplasmodial activity. Eur J Med Chem 2015 Aug 28;101:266-73.
      33. Kaur H, Balzarini J, de Kock C, Smith PJ, Chibale K, Singh K. Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids. Eur J Med Chem 2015 Aug 28;101:52-62.
      34. Kerpel-Fronius S, Rosenkranz B, Allen E, Bass R, Mainard JD, Dodoo A, Dubois DJ, Hela M, Kern S, Massud J, Silva H, Whitty J. Education and training for medicines development, regulation, and clinical research in emerging countries. Front Pharmacol. 2015 Apr 14;6:80.
      35. Lai RP, Meintjes G, Wilkinson KA, Graham CM, Marais S, Van der Plas H, Deffur A, Schutz C, Bloom C, Munagala I, Anguiano E, Goliath R, Maartens G, Banchereau J, Chaussabel D, O'Garra A, Wilkinson RJ. HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. Nat Commun 2015 Sep 24;6:8451.
      36. Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW; Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis 2015 Jun 15;60(12):1860-3.
      37. Maartens G, Meintjes G. Lower-dose efavirenz: what is needed before implementation? Lancet Infect Dis. 2015 Jul;15(7):749-51.
      38. Maartens G, Benson CA. Linezolid for Treating Tuberculosis: A Delicate Balancing Act. EBioMedicine. 2015 Oct 21;2(11):1568-9.
      39. McIlleron H, Abdel-Rahman S, Dave JA, Blockman M, Owen A. Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research. J Infect Dis 2015 Jun 15;211 Suppl 3:S115-25.
      40. Meintjes G, Dunn L, Coetsee M, Hislop M, Leisegang R, Regensberg L, Maartens G. Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. AIDS Res Ther 2015 Dec 1;12:39.
      41. Melariri P, Kalombo L, Nkuna P, Dube A, Hayeshi R, Ogutu B, Gibhard L, deKock C, Smith P, Wiesner L, Swai H. Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. Int J Nanomedicine 2015 Feb 20;10:1493-503.
      42. Mhandire D, Lacerda M, Castel S, Mhandire K, Zhou D, Swart M, Shamu T, Smith P, Musingwini T, Wiesner L, Stray-Pedersen B, Dandara C. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients. OMICS 2015 Sep;19(9):553-62.
      43. Moultrie H, McIlleron H, Sawry S, Kellermann T, Wiesner L, Kindra G, Gous H, Van Rie A. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir. J Antimicrob Chemother 2015 Feb;70(2):543-9.
      44. Mouton JP, Mehta U, Parrish AG, Wilson DP, Stewart A, Njuguna CW, Kramer N, Maartens G, Blockman M, Cohen K. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey. Br J Clin Pharmacol 2015 Oct;80(4):818-26.
      45. Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesseling A, How C, Jean-Philippe P, Lessem E, Makhene M, Mbelle N, Marais B, McIlleron H, McNeeley DF, Mendel C, Murray S, Navarro E, Anyalechi EG, Porcalla AR, Powell C, Powell M, Rigaud M, Rouzier V, Samson P, Schaaf HS, Shah S, Starke J, Swaminathan S, Wobudeya E, Worrell C. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis 2015 Jun;15(6):711-20.
      46. Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, Ferreira H, Maartens G, Mametja D, Meintjes G, Padanilam X, Variava E, Pym A, Pillay Y. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. International Journal of Tuberculosis and Lung Disease 2015;19:979-85. Int J Tuberc Lung Dis 2015;19(8):979–85.
      47. Ongarora DS, Strydom N, Wicht K, Njoroge M, Wiesner L, Egan TJ, Wittlin S, Jurva U, Masimirembwa CM, Chibale K. Antimalarial benzoheterocyclic 4-aminoquinolines: Structure-activity relationship, in vivo evaluation, mechanistic and bioactivation studies. Bioorg Med Chem 2015 Sep 1;23(17):5419-32.
      48. Orrell C, Cohen K, Mauff K, Bangsberg DR, Maartens G, Wood R. A randomised controlled trial of real-time electronic adherence monitoring with text message dosing reminders in people starting first-line antiretroviral therapy. JAIDS 2015;70:495-502.
      49. Pepper DJ, Schomaker M, Wilkinson RJ, de Azevedo V, Maartens G. Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study. AIDS Res Ther 2015 Oct 6;12:35.
      50. Robins AH, Holland M. The enigmatic illness and death of Constance, wife of Oscar Wilde. Lancet 2015 Jan 3;385(9962):21-2.
      51. Shenje J, Ifeoma Adimora-Nweke F, Ross IL, Ntsekhe M, Wiesner L, Deffur A, McIlleron HM, Pasipanodya J, Gumbo T, Mayosi BM. Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. EBioMedicine 2015 Sep 16;2(11):1640-9.
      52. Silal SP, Little F, Barnes KI, White LJ. Hitting a Moving Target: A Model for Malaria Elimination in the Presence of Population Movement. PLoS One 2015 Dec 21;10(12):e0144990.
      53. Silal SP, Little F, Barnes KI, White LJ. Predicting the impact of border control on malaria transmission: a simulated focal screen and treat campaign. Malar J 2015 Jul 12;14:268.
      54. Sinxadi PZ, Leger PD, McIlleron HM, Smith PJ, Dave JA, Levitt NS, Maartens G, Haas DW. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. Br J Clin Pharmacol. 2015 Jul;80(1):146-56.
      55. Stringer T, Taylor D, Guzgay H, Shokar A, Au A, Smith PJ, Hendricks DT, Land KM, Egan TJ, Smith GS. Polyamine quinoline rhodium complexes: synthesis and pharmacological evaluation as antiparasitic agents against Plasmodium falciparum and Trichomonas vaginalis. Dalton Trans. 2015 Sep 7;44(33):14906-17.
      56. Swart M, Evans J, Skelton M, Castel S, Wiesner L, Smith PJ, Dandara C. An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients. Front Genet. 2016 Jan 7;6:356.
      57. Taleli L, de Kock C, Smith PJ, Pelly SC, Blackie MA, van Otterlo WA. In vitro antiplasmodial activity of triazole-linked chloroquinoline derivatives synthesized from 7-chloro-N-(prop-2-yn-1-yl)quinolin-4-amine. Bioorg Med Chem 2015 Aug 1;23(15):4163-71.
      58. Thee S, Garcia-Prats AJ, Draper HR, McIlleron HM, Wiesner L, Castel S, Schaaf HS, Hesseling AC. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin Infect Dis 2015 Feb 15;60(4):549-56. 
      59. Vandekerckhove S, Van Herreweghe S, Willems J, Danneels B, Desmet T, de Kock C, Smith PJ, Chibale K, D'hooghe M. Synthesis of functionalized 3-, 5-, 6- and 8-aminoquinolines via intermediate (3-pyrrolin-1-yl)- and (2-oxopyrrolidin-1-yl)quinolines and evaluation of their antiplasmodial and antifungal activity. Eur J Med Chem 2015 Mar 6;92:91-102.
      60. Wicht KJ, Combrinck JM, Smith PJ Egan TJ4. Bayesian models trained with HTS data for predicting β-haematin inhibition and in vitro antimalarial activity. Bioorg Med Chem 2015 Aug 15;23(16):5210-7.
      61. Wilhelm A, Kendrekar P, Noreljaleel AE, Abay ET, Bonnet SL, Wiesner L, de Kock C, Swart KJ, van der Westhuizen JH. Syntheses and in Vitro Antiplasmodial Activity of Aminoalkylated Chalcones and Analogues. J Nat Prod. 2015 Aug 28;78(8):1848-58.
      62. Wilkinson KA, Walker NF, Meintjes G, Deffur A, Nicol MP, Skolimowska KH, Matthews K, Tadokera R, Seldon R, Maartens G, Rangaka MX, Besra GS, Wilkinson RJ. Cytotoxic mediators in paradoxical HIV-tuberculosis immune reconstitution inflammatory syndrome. J Immunol. 2015 Feb 15;194(4):1748-54.
      63. WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study Group, Adjuik MA, Allan R, Anvikar AR, Ashley EA, Ba MS, Barennes H, Barnes KI, Bassat Q, Baudin E, Björkman A, Bompart F, Bonnet M, Borrmann S, Brasseur P, Bukirwa H, Checchi F, Cot M, Dahal P, D'Alessandro U, Deloron P, Desai M, Diap G, Djimde AA, Dorsey G, Doumbo OK, Espié E, Etard JF, Fanello CI, Faucher JF, Faye B, Flegg JA, Gaye O, Gething PW, González R, Grandesso F, Guerin PJ, Guthmann JP, Hamour S, Hasugian AR, Hay SI, Humphreys GS, Jullien V, Juma E, Kamya MR, Karema C, Kiechel JR, Kremsner PG, Krishna S, Lameyre V, Ibrahim LM, Lee SJ, Lell B, Mårtensson A, Massougbodji A, Menan H, Ménard D, Menéndez C, Meremikwu M, Moreira C, Nabasumba C, Nambozi M, Ndiaye JL, Nikiema F, Nsanzabana C, Ntoumi F, Ogutu BR, Olliaro P, Osorio L, Ouédraogo JB, Penali LK, Pene M, Pinoges L, Piola P, Price RN, Roper C, Rosenthal PJ, Rwagacondo CE, Same-Ekobo A, Schramm B, Seck A, Sharma B, Sibley CH, Sinou V, Sirima SB, Smith JJ, Smithuis F, Somé FA, Sow D, Staedke SG, Stepniewska K, Swarthout TD, Sylla K, Talisuna AO, Tarning J, Taylor WR, Temu EA, Thwing JI, Tjitra E, Tine RC, Tinto H, Vaillant MT, Valecha N, Van den Broek I, White NJ, Yeka A, Zongo I. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med. 2015 Mar 31;13:66.
      64. WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015 Sep 18;13:227.
      65. WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group*: Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data: WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group BMC Medicine 2015 13:212
      66. Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group*: The effect of dose on the antimalarial efficacy of artemether– lumefantrine: a systematic review and pooled analysis of individual patient data: Lancet Infect Dis 2015; 15: 692–702

 

"Leading with Excellence"

Department of Medicine